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Sumário 
 
O cancro de bexiga músculo-invasivo figura um dos tipos de cancro genito-urinários 
mais comuns e com maior taxa de mortalidade. A principal terapêutica utilizada consiste 
em regimes quimio-terapêuticos baseados em cisplatina, que falham na prevenção da 
recorrência e disseminação da doença. Assim, são necessários novos bio-marcadores 
que permitam a estratificação dos doentes e novas estratégias terapêuticas.  
Mais de 70% dos tumores de bexiga musculo-invasivos expressam o antigénio 
Sialil-Tn (STn) em resultado da terminação prematura do processo de elongação das 
cadeias de O- glicanos das proteínas da superfície celular. O antigénio STn demonstrou-
se promotor da invasão celular, da evasão ao sistema imunitário e possivelmente da 
quimio-resistência, constituindo um bio-marcador importante dos fenótipos celulares mais 
agressivos de cancro de bexiga. Contudo, o conhecimento acerca dos acontecimentos 
que promovem esta profunda desregulação dos padrões de glicosilação proteica é 
escasso. Uma vez que a hipóxia é também uma característica proeminente dos tumores 
de bexiga avançados, este trabalho visa compreender de que forma os níveis de oxigénio 
influenciam o glicofenótipo das células tumorais de bexiga, enfatizando a expressão do 
antigénio STn.  
Três linhas celulares tumorais de bexiga com backgrounds genéticos e moleculares 
distintos (T24, 5637 e HT1376) foram submetidas a hipóxia (0.1% O2). Com o objetivo de 
identificar processos mediados pelo HIF-1α, as experiências foram conduzidas 
simultaneamente na presença do estabilizador do HIF-1α Mesilato de Deferoxamina 
(DFX). Em ambas as condições, todas as linhas celulares sobre- expressam o HIF-1α e a 
AC IX, uma proteína altamente HIF-1α – regulada, bem como aumentam a biossíntese de 
lactato, denotando a conversão de metabolismo celular aeróbio para anaeróbio. A hipóxia 
compromete a proliferação celular e potencia a mobilidade/ invasão celular em matrigel. 
Todavia, não se verificam diferenças significativas na atividade das MMP avaliadas em 
hipóxia para todas as linhas celulares, sugerindo estratégias alternativas de mobilidade/ 
invasão. Fizeram-se observações idênticas aquando da exposição das células ao DFX, 
sugerindo que se tratam de eventos HIF-1α- mediados. A análise de um painel de 21 
genes associados a fenótipos estaminais, epiteliais, de transição epitélio-mesenquimal e 
mesenquimal por qRT-PCR revelou que a hipóxia promove a ativação de programas de 
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genes de transição epitélio-mesenquimal e estaminais. Adicionalmente, todas as linhas 
celulares sobre- expressam o antigénio STn de forma HIF-1α- dependente. Porém, o 
aumento dos níveis de STn não está associado à sobre- expressão da principal enzima 
responsáveis pela sua biossíntese, a ST6GalNAC.I, mas sim com a sub-expressão das 
enzimas envolvidas na elongação das cadeias O-glicosídicas. A exposição de células em 
hipóxia ao anticorpo monoclonal anti-STn TKH2 promove um decréscimo dramático na 
mobilidade/ invasão celular, corroborando um papel chave do STn na disseminação da 
doença. A associação entre a hipóxia, evidenciada pela sobre-expressão de HIF-1α, e a 
sobre-expressão de STn foi clinicamente confirmada em tecidos tumorais por imuno-
histoquímica. 
No seu conjunto, estes dados indicam que a hipóxia não só favorece a aquisição de 
um fenótipo mesenquimal mas também compromete a O-glicosilação proteica como uma 
forma de conferir ás células maior mobilidade/ capacidade invasiva. Por fim, uma análise 
glicoproteómica preliminar por western blot, sob o ponto de vista da expressão de STn, 
revelou que células em hipóxia sobre- expressam proteínas STn positivas de baixo peso 
molecular (<50 kDa) em relação à normóxia, o que poderá permitir atingir seletivamente 
células em hipóxia prevenindo a disseminação da doença. 
Em resumo, o presente trabalho reafirma a relevância clinica do antigénio STn no 
cancro de bexiga musculo-invasivo. Apresenta-se ainda um novo mecanismo, baseado na 
modulação da O-glicosilação proteica e na expressão de STn, através do qual a hipóxia 
contribui para a agressividade dos tumores de bexiga. Adicionalmente, este trabalho 
realça a necessidade de se explorar o glicoproteoma de células hipóxicas visando o 
desenvolvimento de bio- marcadores capazes de melhorar a gestão do cancro de bexiga. 
  
 
Palavras-chave 
Cancro de bexiga; Hipóxia; Sialil-Tn; Glicosilação e metabolismo; Glicosilação 
proteica, Glicanas associados a cancro, HIF-1α 
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Abstract 
 
Muscle invasive bladder cancer (MIBC) is amongst the most common and deadliest 
genitourinary cancers. The mainstay treatment is surgery and cisplatin-based regimens, 
which fail in avoiding tumour relapse and disease progression, urging for novel biomarkers 
for accurate patient stratification and new therapeutics. 
Over 70% of MIBC express the cell-surface tumour-associated carbohydrate antigen 
Sialyl-Tn (STn) that stems from a premature stop in the O-glycosylation of cell surface 
proteins. STn was found to be a promoter of cell invasion, immune escape, and possibly 
chemotherapy resistance, making it an attractive biomarker for aggressive cellular 
phenotypes. However, there is scarce information about the events underlying this 
profound deregulation in protein glycosylation. Based on the fact that hypoxia is also a 
salient feature of advanced stage bladder tumours, this work devotes to understanding 
how oxygen levels influences the glycophenotype of bladder cancer cells, with emphasis 
on the STn antigen.  
Three bladder cancer cell lines with distinct genetic and molecular backgrounds 
(T24, 5637 and HT1376) were submitted to hypoxia (0.1% O2). In an attempt to determine 
HIF-1α-mediated events, experiments were also conducted in the presence of the HIF-1α 
stabilizer Deferoxamine Mesilate (DFX). In both conditions all cell lines overexpressed 
HIF-1α and its regulated protein CA IX, and increased lactate biosynthesis, denoting a shift 
to an anaerobic metabolism. Hypoxia also impaired cell proliferation and enhanced 
motility/invasion in matrigel; however no significant differences were observed in MMP 
activity in hypoxia for all cell lines, denoting alternative motility/invasion-promoting 
strategies. Similar observations were made in the presence of DFX, suggesting these are 
HIF-1α-mediated events. The analysis of a panel of 21 genes associated with stem, 
epithelial, epithelia-to-mesenchymal (EMT) and mesenchymal phenotypes by quantitative 
polymerase chain reaction (qPCR) showed that hypoxia led to the activation of EMT/stem 
cell programs. Concomitantly, all cell lines overexpressed the STn antigen, in an HIF-1α-
dependent manner. However, STn elevations did not associate with an overexpression of 
its main biosynthesis enzyme ST6GalNAC.I, but with a significant down-regulation of the 
enzymes involved in O-glycan elongation. The exposure of hypoxic cells to anti-STn 
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monoclonal antibody TKH2 promoted a dramatic decrease in cellular motility/invasion, 
supporting a key role for STn in disease dissemination. The associations between hypoxia, 
based on the nuclear overexpression of HIF-1α, and STn in MIBC were further confirmed 
by immunohistochemistry in patient samples.  
Collectively this data shows that hypoxia not only favours a mesenchymal phenotype 
but also antagonizes protein O-glycosylation as a strategy to endow cells with higher 
motility/invasive potential. Finally, a preliminary STn-glycoproteomic analysis by western 
blot highlighted that hypoxic cells overexpressed low molecular weight STn-proteins (<50 
kDa) in relation to normoxia, that may offer potential to selectively target hypoxic cells and 
consequently avoid disease dissemination. 
In resume, the present work reaffirms the clinical relevance of STn antigen in MIBC. 
It also presents a new mechanism, based on the modulation of protein O-glycosylation and 
STn expression, by which hypoxia contributes to bladder cancer aggressiveness. 
Furthermore, it highlights the need to mine the glycoproteome of hypoxic cells for highly 
specific theranostic biomarkers capable of improving bladder cancer management.  
 
Key-words 
Bladder cancer; Hypoxia; Sialyl-Tn, Glycosylation and metabolism, Protein 
glycosylation, Cancer-associated glycans, HIF-1α. 
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I. Introduction 
 
1.1. Bladder cancer epidemiology and disease 
information 
 
1.1.1. Epidemiology 
 
Bladder cancer (BC) is the most common malignancy of the urinary tract and the 7th 
most common cancer in men and the 17th in women (1). The incidence of BC increases 
with age, reaching a peak between 50 and 70 years, and is three times more common in 
men than in women (2).  
Environmental factors are thought to play a significant role in BC initiation. Chemical 
or environmental/occupational exposures and chronic inflammation are well known risk 
factors for the development of BC and they may lead to genetic and molecular changes, 
which irreversibly convert a normal urothelial cell to one with a malignant phenotype. 
Chemical and environmental exposures include aromatic amines, aniline dyes, nitrites and 
nitrates, acrolein, coal, and arsenic. Other causal factors include indwelling catheters, 
Shistosomiasis (Schistosoma haematobium infection), and pelvic irradiation (3). 
Notwithstanding all these factors, in Western world cigarette smoking is the most relevant 
risk factor, accounting for approximately 50% of BC cases (1).Genetic predisposition also 
has a significant influence on BC, especially via its impact on susceptibility to other risk 
factors (4). 
 
1.1.2. Pathophysiology and progression of Bladder Cancer 
 
Urothelial cancers arise through two distinct but somewhat overlapping pathways 
that are driven by different genetic changes: papillary and non-papillary. Approximately 
80% to 85% of urothelial cancers are papillary lesions, which arise from hyperplastic 
epithelium with the expansion of a preneoplastic clone, which shows minimal phenotypic 
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deviation from normal urothelium. The continuous growth of such clone results in the 
development of low-grade superficial papillary tumours that harbour frequent mutations in 
the Fibroblast Growth Factor 3 (FGFR3) (~70%), Harvey rat sarcoma viral oncogene 
homolog (HRAS) (30-40%) and phosphoinositide-3-kinase (PI3KCA) genes (5). Non-
papillary and invasive tumours usually arise from severe dysplasia or carcinoma in situ 
(CIS). In a non-papillary pathway, a successive subclone of the initial hyperplasia develops 
genetic instability with frequent loss of major tumour suppressor genes as Retinoblastoma 
(RB) and p53 (~ 50%). The vast majority of invasive bladder cancers occur in patients 
without a prior history of papillary tumours (6). 
Macroscopic (frank or gross) haematuria is the commonest presenting sign of BC, 
occurring in about 75% of patients. More than 90% of diagnosed bladder cancers are 
transitional cell carcinomas (currently classified as high-grade urothelial cell carcinomas 
according to WHO guidelines), 5% are squamous cell carcinomas, and less than 2% are 
adenocarcinomas. Of all newly diagnosed cases of urothelial carcinomas, about 70% are 
superficial tumours (stages Ta, T1, or tumours in situ [Tis]), but as many as 50–70% of 
those superficial tumours will recur and roughly 10–20% will progress to muscularis 
propria invasive disease (T2–4) usually with metastasis (as well as localized persistent 
disease) within a median of 2 years if managed only by transurethral resection and 
intravesical therapy (7). Consequently, non-muscle invasive bladder cancer (NMIBC) is a 
chronic disease with varying oncologic outcomes requiring frequent follow-up and 
repeated treatments, making the cost per patient from diagnosis to death the highest of all 
cancers (8). Increasing tumour grade, stage, size and multifocality have been associated 
with an increased risk of progression. 
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Figure 1. Transitional cell carcinoma staging by the tumour-node-metastasis (TNM) staging system, in which the stage of the 
primary tumour (T) is based on the extent of penetration or invasion into the bladder wall (9).Tis, Tumour in situ: ‘‘flat 
tumour’’; Ta, Non-invasive papillary carcinoma; T1, Tumour invades subepithelial connective tissue; T2, Tumour invades 
muscle; T2a, Tumour invades superficial muscle (inner half); T2b, Tumour invades deep muscle (outer half); T3, Tumour 
invades perivesical tissue; T4, Tumour invades any of the following: prostate, uterus, vagina, pelvic or abdominal wall. 
 
1.1.2.1. Diagnosis, management and therapeutics of BC 
 
Primary treatment of Ta/T1 transitional cell carcinoma is endoscopic resection of the 
bladder tumour. Further management is based upon risk factors discussed above and 
stage/grade of the disease. Depending on these, a patient may need only surveillance, 
single-installation of intravesical chemotherapy, a course of intravesical chemotherapy or 
immunotherapy or further surgery. The most commonly used and recommended 
intravesical therapy is the administration of the live attenuated bacillus Calmette-Guérin 
(BCG) causing an extensive local inflammatory reaction in the bladder wall. While the 
precise mechanism of BCG action is unclear, studies have implicated natural killer cells 
and T lymphocytes as critical mediators of the anti-tumour immune response (10). 
However, only two thirds of patients respond to BCG and one third of the responders will 
have recurrent disease. Recurrence after BCG treatment is associated with a poor 
prognosis (11). 
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In patients with low grade Ta disease, the 15-year progression-free survival is 95% 
with no cancer-specific mortality. Patients with high grade Ta tumours have a progression-
free survival of 61% and a disease-specific survival of 74%, whereas patients with T1 
disease have a progression-free survival of 44% and a disease-specific survival of 62%, 
lending support to the view that invasion of the lamina propria is a prognostic indicator for 
risk of disease progression and reduced survival (3). 
Once transitional cell carcinoma invades the muscle of the bladder wall (T2), 
perivesical tissue (T3) or adjacent pelvic organs (T4), it cannot be controlled by 
endoscopic resection and intravesical treatment alone (12). The standard surgical 
approach to treatment of muscle-invasive bladder cancer is radical cystectomy. For 
patients who undergo total or partial resection of the bladder, treatment with adjuvant (after 
surgery) or neoadjuvant (before surgery) chemotherapy is also an option (12). 
Approximately 30% of patients with urothelial cancer present muscle-invasive 
disease, and about half relapse after radical cystectomy, depending on the pathological 
stage of the primary tumour and the presence of loco-regional or distant metastasis. Local 
recurrence accounts for approximately 30% of relapses, whereas distant metastasis are 
more common. Ten to fifteen percent of patients are already metastatic at diagnosis. 
Before the development of effective chemotherapy, patients with metastatic urothelial 
cancer rarely had a median survival that exceeded 3-6 months (13). 
Advanced bladder cancer may metastasize to lymph nodes (usually pelvic), or via 
vascular spread to the liver, lung, bone and intestines or other organs. Patients with good 
renal function may be suitable for systemic chemotherapy with cisplatin-based 
combinations (methotrexate, vinblastine, cisplatin, doxorubicin, i.e. the MVAC regime or 
gemcitabine/cisplatin, GC). MVAC and GC prolonged survival up to 14.8 and 13.8 months, 
respectively, compared to monotherapy and other combinations. Response rates were 
46% and 49% for MVAC and GC, respectively. The major difference between the above-
mentioned combinations is toxicity. The lower toxicity of GC has resulted in it becoming a 
new standard regimen. Even though chemotherapy is efficient against highly proliferative 
malignant cells that form the tumor bulk, the five-year overall survival does not exceed 
25% and many patients die prematurely from adverse drug reactions (14) urging for 
effective and safe targeted therapeutics. 
Modest disease control rates, with sporadic marked chemotherapy responses has 
led to the investigation of biomarkers for assessment of postoperative prognosis and the 
potential value of perioperative chemotherapy, and as predictors of response to 
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chemotherapy or its monitoring. Most of the biomarkers are associated with tumour 
angiogenesis. Small studies, usually retrospective, have investigated microvessel density, 
altered p53 tumour expression, serum vascular endothelial growth factor, urinary and 
tissue basic fibroblast growth factor, urinary (wild-type and mutant) and tissue fibroblast 
growth factor receptor-3, and more recently, thrombospondin-1, circulating tumour cells, 
and multidrug resistance gene expression. More recently, it was also reported that over 
75% of MIBC express the sialyl-Tn antigen that stems from profound alterations in the O-
glycosylation (linked to Ser/Thr residues) of cell-surface proteins that appears to have 
implications in cell behaviour towards invasion and migration (15). Although some 
biomarkers have shown predictive potential, none has sufficient evidence to support its 
routine clinical use in diagnostics or to develop novel therapeutics.  
Despite the several studies on pathways associated to invasion and metastasis for 
prognostic and predictive biomarkers of response to chemotherapy, few have addressed 
the influence of microenvironment factors. In particular, the role of hypoxia, a known 
promoter of drug resistance, invasion and metastasis in solid tumours (16), remains poorly 
understood in the context of bladder cancer.  
 
1.2. Hypoxia: an hallmark of cancer 
progression and dissemination 
 
1.2.1. HIFs and cellular O2 sensing  
 
Hypoxia is defined as a reduction of oxygen tension available to a cell, tissue or 
organism. At the atmospheric pressure (150 mm Hg), ambient air consists of 21% O2 
however in most mammalian tissues O2 percentage is around 2%–9% (on average 40 mm 
Hg). Hypoxia is usually defined as ≤ 2% O2 and severe hypoxia (or anoxia) is defined as ≤ 
0.02% O2. Depending on regional and temporal status of blood flow through tortuous 
vessels, hypoxia can vary from moderate to severe, acute to chronic, and intermittent to 
persistent. Low O2 tensions are normally associated to intense inflammation or necrotic 
regions as well as to less vascularized regions of the bone marrow. In solid tumours, 
hypoxia results from of an inadequate supply of oxygen, due to exponential cellular 
proliferation and an inefficient vascular structure. Both acute and chronic hypoxia co-exist 
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within a tumour, resulting in differential gradients of oxygen consumption and contributing 
to intra-tumour heterogeneity.  
Although hypoxia is toxic to both cancer and normal cells, when tissue metabolism 
exceeds metabolic supply, the hypoxic response triggers a series of changes in gene 
transcription or protein posttranslational modifications, conducting to changes of cell 
metabolism, ultimately protecting against cell death. This response to the decline of O2 
levels is in part mediated by heterodimeric transcription factors known as hypoxia-
inducible factors (HIFs) comprised by an α and a β subunit. In mammals, there are three 
O2-regulated HIFα subunits. While HIF-1α is ubiquitously expressed, HIF-2α is restricted to 
vascular endothelium, liver parenchyma, lung type II pneumocytes and kidney epithelial 
cells and HIF-3α is found at high levels in the thymus, cerebellar Purkinje cells and the 
corneal epithelium of the eye. Heterodimers that contain HIF-1α or HIF-2α seem to have 
overlapping but distinct specificities, with regard to physiological inducers and target gene 
activation. The third related protein, HIF-3α, might function primarily as an inhibitor of HIF-
1α. Instead, HIF1β is constitutively expressed and insensitive to changes in O2 levels (17–
21). 
 
1.2.2. HIF-1-alpha and mechanism of hypoxia sensing 
 
Under normal O2 tensions, prolyl hydroxylase domain enzymes (PHDs) hydroxylate 
two conserved proline residues (405 and 531 in HIF-1α) within the O2-dependent 
degradation (ODD) domain of the HIF-α subunit in an O2- and 2-oxoglutarate-dependent 
manner. After hydroxylation, the von Hippel-Lindau (VHL) tumour suppressor E3 ligase 
complex polyubiquitinates HIF-α and targets it for degradation by the 26S proteasome. 
Moreover, the O2-dependent hydroxylation of the asparagine (N) residue 803 in HIF-1α by 
the enzyme FIH-1 (Factor Inhibiting HIF-1) blocks the binding of p300 and CBP to HIF-1α 
and therefore inhibits HIF-1α gene transcription. Under low O2 tension, HIFs are no longer 
modified by PHDs, but instead dimerize with ARNT/HIF-1β through HLH and PAS domain 
interactions, translocate to the nucleus, and recruit co-activators such as CBP/p300. HIF 
heterodimers bind and recognize hypoxia-response elements (HREs), with the consensus 
sequence G/ACGTG, within the promoter regions of target genes and drive adaptive gene 
transcription. Some well-known examples include vascular endothelial growth factor 
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(VEGF; involved in angiogenesis), GLUT1 (also known as SLC2A; a glucose transporter 
involved in glycolysis) and carbonic anhydrase IX (CA9; a regulator of cellular pH) (22–24). 
 
 
 
 
Figure 2. HIF regulation is primarily based on post-translational modification and protein stability (25). CBP, cyclic AMP 
response-element binding protein; CUL-2, cullin-2; E1, ubiquitin-activating enzyme; E2, ubiquitin-conjugating enzyme; HIF-α, 
hypoxia-inducible factor alpha; ARNT/HIF-1β, hypoxia-inducible factor-1beta; HRE, hypoxia response element; O2, oxygen; 
OH, hydroxyl ions; p300, a histone acetyltransferase closely related to CBP; Poll II, RNA polymerase II; Rbx1, really 
interesting new gene (RING)-box protein 1 (or regulator of cullin 1); Ub, ubiquitin; VHL, von Hippel–Lindau protein; Anti-HIF-
1α RNA, αHIF, a natural anti- sense transcript (NAT) complementary to the 3' untranslated region of the HIF1α, negatively 
regulates the expression of HIF1α. Overexpression of αHIF triggers HIF1α mRNA decay and HIF1α and αHIF constitute a 
negative feedback loop(26). 
 
It is relevant to evidence that the activation of HIF is not only induced by hypoxic 
conditions. Moreover, whereas hypoxia ubiquitously increases HIF-1α levels by decreasing 
its molecular degradation, growth factors, cytokines and other signalling molecules, also 
induce HIF-1α expression in a cell-type specific manner. HIF-1α levels can increase by 
dysfunctional tumour suppressor genes (e.g., VHL, SDHB, SDHC, SDHD, FH, IDH1, P53, 
TSC2, PTEN and LKB1) as well as by proteins of oncogenic viruses (e.g., EBV latent 
membrane protein 1, hepatitis B virus X protein, human papillomavirus E6/E7 protein, 
human T-cell leukemia virus tat protein, KSHV G protein-coupled receptor, KSHV latency-
associated nuclear antigen and KSHV viral interferon regulatory factor 3). Furthermore, 
HIF can be activated by two additional mechanisms: oncogenic signalling, including the 
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mitogen-activated protein kinase (MAPK: RAS/MNK) and PI3K/AKT pathways and 
constitutive oncogene induced signalling, including the loss of tuberous sclerosis complex 
1 or 2 (TSC1 or 2) function, inactivation of VHL (in the Von Hippel-Lindau disease), 
accumulation of fumarate (in hereditary leiomyomatosis renal-cell cancer syndrome 
[HLRCC]) or accumulation of succinate (in hereditary paraganglioma syndrome).  
It is also worth mentioning that although HIFs are crucial mediators of the 
transcriptional response to hypoxia, a number of HIF-independent pathways also respond 
to changes in O2 tension. These responses allow cells to acutely adapt to the energetic 
demands of decreased O2 availability by reducing and limiting energy-consuming 
processes such as protein synthesis. There are two distinct pathways leading to this 
inhibition of translation. The first is rapid, HIF1α-independent, and mediated by the 
‘unfolded protein response’ (UPR). On its turn UPR mediates the phosphorylation of the 
eukaryotic initiation factor 2α (EIF2α) by the endoplasmic reticulum kinase PERK (also 
known as EIF2A kinase 3 (EIF2AK3)), leading to inhibition of mRNA translation initiation. 
The second pathway consists of a delayed response, only activated after prolonged 
(chronic) hypoxia. This response is associated with disruption of the mRNA cap-binding 
complex, EIF4F, which inhibits the transcript recruitment step of mRNA translation (27). 
 
1.2.3. Role of hypoxia in the hallmarks of human cancer 
 
Hypoxia has been recognized as one of the fundamentally important features of solid 
tumours, exerting a critical role in various cellular and physiologic events, including cell 
proliferation and differentiation, survival, angiogenesis, immunosurveillance, and 
metabolism. Moreover, it also influences tumour invasion, metastasis and resistance to 
radiotherapy and certain chemotherapies. Overall, hypoxia may contribute to promote and 
select for a more aggressive phenotype of tumour cell and it is an adverse prognostic 
indicator in cancer. 
 
Apoptosis evasion 
 
In contrast to normal cells, cancer cells can break the balance between pro- and 
anti-apoptotic factors to escape HIF-1α-mediated apoptosis under adverse conditions, 
such as hypoxic stress. Several pro-apoptotic (e.g. BNIP3, NIX, and NOXA) as well as 
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anti-apoptotic factors (e.g. BaK, Bax, Bcl-xL, Bcl-2, Bid, Mcl-1, NF-kB, p53 and survivin) 
are regulated by HIF-1α. However, in the vast majority of transformed cells, HIF-1α 
functions as a major suppressor of apoptosis (28). For example, hypoxia can up-regulate 
the expression of the p53-negative regulator MDM2, increasing cell resistance to 
apoptosis in vivo and promoting metastasis or induce the expression of the anti-apoptosis 
protein IAP-2. Additionally, hypoxic cancer cells also activate the PI-3K/Akt survival 
pathway, a critical regulator of cell survival and proliferation (29–31). During hypoxia-
induced apoptosis, only the phosphorylated HIF-1α binds to HIF-1β. By contrast, the 
dephosphorylated form of HIF-1α binds to and stabilizes p53, inducing a p53-dependent 
apoptosis, which is mediated by APAF-1 and caspase-9. Moreover, p53 directly interacts 
with HIF-1α and blocks HIF-1α’s ability to activate transcription of anti-apoptotic genes. 
Hypoxia acts then as a selective pressure during tumour growth, eliminating cells with 
wild-type p53 and selectively and clonally expanding cells with mutant or otherwise 
inactive p53, therefore evading p53-dependent apoptosis and transcription blockage 
(32).These and many other experimental results give further evidence for the major role 
played by hypoxia in facilitating tumour cell survival by evading the apoptotic pathway. 
 
Limitless replicative potential 
 
Human somatic cells normally have a finite replicative potential. However, cancer 
cells can overcome this obstacle, fail to senesce and acquire limitless replicative potential 
by increasing telomerase activity in a HIF-1α-dependent manner (27,33). Despite 
numerous descriptions of telomerase expression within human tumours and cancer cell 
lines, the mechanisms of regulation are largely unknown. In a hypoxic microenvironment, 
cancer cells can also overexpress mitogenic growth factors such as EGF, insulin, IGF-1, 
IGF-2, and PDGF, or constitutively activate the downstream pathways of these growth 
factors in order to maintain their proliferative potential. Moreover, HIF-1α is involved in the 
autocrine growth-factor stimulation of cancer cells, through which binding of growth-factors 
ligands, such as IGF2 and TGF-α, to their cognate receptors stimulates the expression of 
HIF-1α. This leads to increased HIF-1α transcriptional activity of target genes, which 
include those that encode IGF2 and TGF-α (34).  
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Angiogenesis induction  
 
Normally, tumour vasculature is structurally and functionally inefficient, leading to 
abnormal perfusion and tumour hypoxia. In response to this challenging 
microenvironment, a number of angiogenic factors are induced such as VEGF, IL-8, 
angiogenin, FGF, and PDGF (16). Besides promoting up-regulation of VEGF and one of its 
receptors, VEGF receptor 1 (VEGFR1/FLT-1), HIF-1α activity can also decrease the 
activity of the angiogenic inhibitor thrombospondin to create a pro-angiogenic 
microenvironment. Moreover, there are two different models that explain the initiation or 
acceleration of angiogenesis in a hypoxic microenvironment, the hypoxic crisis model and 
the acceleration model (35). In the vascular crisis model, hypoxia can induce VEGF to 
promote the initiation of angiogenesis. On the other hand, the acceleration model 
proposes that hypoxia is not responsible for initiation of angiogenesis and that this 
initiation is driven by non-hypoxia-mediated mechanisms, such as the induction of VEGF 
by oncogene activation. Once angiogenesis is initiated, cancer cells grow quickly, resulting 
in additional hypoxia, while HIF-1α levels increase to accelerate angiogenesis 
(17,19,23,36–38). Hypoxia-induced angiogenesis is blocked by inhibitors of oncogenic 
signalling pathways, such as RAS, epidermal growth factor receptor, and the tyrosine 
kinase receptor ERBB2 (HER2/neu) inhibitors. This indicates that there is crosstalk 
between oncogenic and hypoxia-response pathways. 
 
Immunosurveillance evasion 
 
The tumour microenvironment involves several cell types, including cancer cells, 
endothelial cells, immune cells, and stromal elements. The co-existence of tumours and 
anti-tumour immune cells (“Hell- strom Paradox”) has been a challenging problem for a 
long time (39). This paradox prompted speculations that tumour microenvironment in vivo 
may prevent anti-tumour CD8+ T cells cytotoxic activity (40). Monocytes are also 
continually recruited into tumours where they differentiate into tumour-associated 
macrophages (TAMs), and accumulate in these hypoxic areas. It is now known that 
macrophages respond to the levels of hypoxia found in tumours by acquiring a pro-tumour 
phenotype in which they up-regulate HIF-1α and HIF-2α which in turn activate a broad 
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array of mitogenic, pro-invasive, pro-angiogenic, and pro-metastatic genes (41). Hypoxia 
may also inhibit the ability of macrophages to phagocyte and present antigens to T cells, 
reducing their pro-inflammatory capacity (42). The complex mechanisms by which cancer 
cells evade the immune response under hypoxic microenvironment are still poorly 
understood. However, one possibility may be that cancer cells secrete various 
immunosuppressive factors by HIF-1α-dependent pathways, such as hypoxia-induced 
extracellular adenosine. Other possibility is the activation of HIF-independent pathways, 
that protect cancer cells from immune damage by the same mechanism which protects 
normal tissues from the excessive collateral damage by overactive immune cells during 
acute inflammation (40). These and other findings suggest that not only malignant cells but 
also immune cells adapt to hypoxic microenvironments and promote the expression of 
factors that are necessary to escape immunosurveillance (43). Additionally, inflammatory 
cytokines are significantly enhanced in hypoxic or inflammatory states, and their 
constitutive expression is a characteristic of many malignant tumours and often associates 
with tumour progression, metastasis and poor prognosis (44). Inflammatory cytokines 
including TNFα, TGFβ, IL-1, IL-6 and IL-8, secreted by inflammatory cells in tumours sites 
such as neutrophils, lymphocytes, macrophages and myeloid-derived suppressor cells 
(MDSC) might play an essential role in a hypoxia-induced phenomenon called epithelial-
mesenchymal transition (EMT) that will be latter on explored (45).  
 
Radioresistance and Chemoresistance 
 
Under normoxic conditions, ionizing radiation (IR) produces DNA double-strand 
breaks (DNA DSBs), DNA single-strand breaks (DNA SSBs), DNA base damage, and 
DNA–DNA and DNA–protein crosslinks (DPCs). The ionizing radiation generates ROS that 
lead to DNA DSB and consequently cell death. Under hypoxic conditions, O2 shortage 
translates into decreased ROS production, which negatively affects treatment efficacy 
(46). It is thought that fractionated radiotherapy partially overcomes intratumoural 
radioresistance because radioresistant hypoxic cells become reoxygenated, and therefore 
resensitized between individual dose fractions. Hypoxic genes expression can also modify 
cellular radioresponse, in a HIF-1α-dependent manner, by promoting ATP metabolism 
during fractionated radiotherapy, proliferation, p53 activation, and by stimulating 
endothelial cell survival (27). A number of factors associated either directly or indirectly 
with tumour hypoxia also contribute to an overall decrease of the efficacy of 
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chemotherapeutic agents in vivo. Some factors include; i) decreased drug action in the 
absence of O2, ii) decreased effect of agents in hypoxic cells that are poorly proliferating or 
have altered pH gradients, iii) induction of gene amplification, and iv) an overall decreased 
drug diffusion and delivery to cells distant from functional vasculature (47). Moreover, HIF-
1α is able to activate the multidrug resistance 1 (MDR1) gene that encodes a membrane-
resident P-glycoprotein (P-gp) that belongs to the family of ATP-binding cassette (ABC) 
transporters. On its turns, P-gp decreases the intracellular concentration of several 
chemotherapeutic drugs by acting as drug efflux pump. Multidrug-resistance-associated 
protein 1 (MDRP1) is another ABC transporter related with HIF-1α-mediated drug 
resistance (28). Earlier studies also reported that transient hypoxia induces DNA over-
replication and amplification of a drug resistant gene encoding dihydrofolate reductase. 
HIF-1-mediated alteration in cell proliferation and survival represent other pivotal causes 
for drug resistance. The relative importance of each factor might depend on the duration of 
hypoxic exposure (such as acute versus chronic) (27,32). 
 
Genetic instability 
 
The cause of human cancers is imputed to the genetic alterations at nucleotide and 
chromosomal levels of ill-fated cells. It has long been recognized that genetic instability is 
responsible for the cellular changes that confer progressive transformation on cancerous 
cells (48). Hypoxia is one of the most important microenvironmental factors that can drive 
genetic instability and its role in gene amplification, DNA breaks at chromosomal fragile 
sites and disruption of DNA damage repair is well established (49).  
Mutation in human DNA mismatch repair (MMR) genes such as MLH1, MSH2, and 
MSH6 are associated with the development of both hereditary and sporadic cancers and 
it’s well known that hypoxia/ ischemia impairs the MMR system by inhibiting gene 
expression (50,51). Moreover, it has been reported that MutSα, MSH2 and MSH6 genes 
responsible for MMR initiation, are specifically down-regulated by hypoxia via the HIF-1α-
Myc pathway (52). Hypoxic stress can also suppress the nucleotide excision repair (NER) 
pathway. It is hypothesized that the unique metabolic conditions induced by hypoxia (e.g., 
decreased adenosine triphosphate [ATP] production) may impair the enzymatic activity of 
specific NER proteins, leading to a functional decrease in NER repair under these 
conditions (53). In addition to genetic changes at the nucleotide levels, chromosomal 
instability is more commonly observed in cancers. Moreover, cancer-associated hypoxia 
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induces additional chromosomal breakage and rearrangement during replication stress at 
regions called chromosomal fragile sites (54). Therefore, hypoxia-induced DSBs may 
contribute to a later stage of tumour progression, by inducing chromosomal instability 
mainly due to impairment of DSBs repair (49). DSBs are mostly repaired by homologous 
recombination (HR) or non-homologous end-joining (NHEJ) pathways in a cell cycle-
dependent manner. The proteins RAD51, BRCA1/2 and the MRN complex (MRE11, 
RAD50, NBS1) together regulate HR during S and G2 phases of the cell cycle and 
proteins such as KU70/80, DNA-PKcs and DNA-ligase IV function in NHEJ across all 
phases of the cell cycle (55,56). The majority of HR proteins are repressed by chronic 
hypoxia through decreased transcription, translation, miRNA modulation and epigenetic 
silencing (57). Altogether HR pathway repression is associated with substantial 
suppression of recombinational repair activity in hypoxic cells. Other chromatin responses 
to hypoxia include global deacetylation and methylation of histones. Moreover, histone 
deacetylases (HDACs), implicated in alteration of chromatin assembly and tumorigenesis, 
are activated by hypoxia (58,59). Premature condensation of chromosomes and abnormal 
chromosome mis-segregation are also common features of hypoxic cells (27). 
 
Glycolysis and pH regulation 
 
As already stated, cells undergo a variety of biological responses towards hypoxic 
conditions, however the earliest recognized pathway was that hypoxic cells undergo a shift 
from aerobic to anaerobic metabolism. Metabolic adaptation represents a canonical 
response to hypoxia, which includes a more or less dramatic shift toward the glycolytic 
metabolism that enables the sustained, although less efficient production of energy (60). 
Hypoxic cancer cells use glycolysis as a primary mechanism of ATP production without the 
need for O2-dependent oxidative phosphorylation, and HIFs are master regulators of 
glucose metabolism during hypoxia. HIF-1α activates transcription of genes encoding 
glucose transporters (GLUT1 and GLUT3), which mediate cellular glucose uptake, and 
other glycolytic enzymes such as lactate dehydrogenase A (LDHA), phosphoglycerate 
kinase 1 (PGK-1), and hexokinase 1 (HK1) and thus plays an important role in the 
glycolytic switch (61,62). Hypoxia and HIF-1α increase glucose/carbon flux through the 
glycolytic pathway while minimizing input into the tricarboxylic acid cycle (TCA) and 
oxidative phosphorylation. The up-regulation of pyruvate dehydrogenase kinase (PDK1) 
which in turn deactivates pyruvate dehydrogenase (PDH), the enzyme responsible for 
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conversion of pyruvate to acetyl-CoA, redirects glucose away from the oxidative 
phosphorylation pathway (61,63). HIF-1α has also been shown to collaborate with c-Myc 
oncogene to active hexokinase 2 (HK2) as well as PDK1, resulting in increased conversion 
of glucose to lactic acid (64). Moreover, glycolysis also provides substrates for biosynthetic 
reactions (e.g. nucleotides, amino acids, and lipids) and thereby facilitates cell proliferation 
in the process of tumour expansion (65). In addition, hypoxia leads to selection of 
inherently glycolytic cells developed through oncogene-mediated, hypoxia-independent 
HIF-1α stabilization (66). These are the reasons why tumour cells maintain glycolytic 
metabolism even in the presence of oxygen and why they do not switch back to oxidative 
phosphorylation under aerobiosis. Nevertheless, some tumour cells strongly rely on uptake 
of glutamine and glutaminolysis, which supports the mitochondrial TCA cycle and pentose 
phosphate pathway and thereby facilitates the synthesis of fatty acids, nonessential amino 
acids and nucleosides (67). Although HIF-1α strongly links aerobic glycolysis to 
carcinogenesis, it would be premature to conclude that the glycolytic phenotype in cancer 
cells is invariably due to deregulation of the HIF system. 
In addition, glycolysis is thought to be the main mechanism by which tumours lower 
their pH, through generation of lactic acid. Carbonic Anhydrases (CA), which are 
metalloenzymes that catalyse the reversible hydration of carbon dioxide to bicarbonate 
ions and protons, might also be involved. CA IX is one of the 15 human isoforms of the 
carbonic anhydrase family and it is not expressed in the majority of normal tissues. 
Actually, it is abundant only in the stomach and gallbladder epithelia. On the other hand, it 
is very often and strongly expressed in tumours, generally in the more aggressive forms 
(68). HIF-1α is the essential transcription factor of the CA9 gene driving its transcription in 
response to intra-tumour hypoxia or inactivating mutation of the VHL tumour suppressor 
gene. Recently, the hypoxia-induced CA9 transcription was found to be dependent on the 
cooperation between HIF-1α and an intracellular domain of Notch3 (NICD3), a 
transcription factor involved in cell-fate determination, morphogenesis, and oncogenesis 
(69). Importantly, hypoxia also regulates CA9 expression by post-transcriptional 
mechanisms through splicing and mRNA stabilization. Accumulating experimental 
evidence supports the direct participation of CA IX in many hypoxia- and acidosis-induced 
features of tumour phenotype, including increased adaptation of tumour cells to 
microenvironmental stresses, resistance to therapy, increased tumour cell migration and 
invasiveness. Moreover, increased focal adhesion during cell spreading, destabilization of 
intercellular contacts, maintenance of stem cell phenotype, tumour–stroma crosstalk, 
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signal transduction and possibly other cancer-related phenomena (22). For example, 
extracellular acidosis mediated by CA can activate the proteolytic enzymes (some of them 
being transcriptionally induced by hypoxia) that degrade extracellular matrix and facilitate 
invasion of tumour cells across the basal membrane and through the surrounding normal 
tissue (70,71). CA IX also contributes to therapy resistance in a way that tumours 
expressing high CA IX levels are less responsive to experimental therapy, and inhibition of 
CA IX catalytic activity significantly improves their chemo- or radiosensitivity (68). Hypoxia 
and extracellular acidosis also contribute to cancer cell dedifferentiation toward the stem 
cell-like phenotype and CA IX was shown to be involved in this phenomenon in breast 
(72), bladder (73) and esophageal carcinoma models (73). Expression of CA IX correlates 
with the expression of a stem cell marker CD44 and CA IX targeting by inhibition of its 
catalytic activity results in the inhibition of breast cancer stem cell expansion in hypoxia, 
indicating that pH-regulating function of CA IX is required for the maintenance of stemness 
(22,74). 
 
 
Figure 3. Genes that are involved in many essential processes are direct HIF-1α targets (75). Four groups of direct HIF-1 
target genes particularly relevant to cancer encode: angiogenic factors, glucose transporters and glycolytic enzymes, 
survival factors and invasion factors. ADM, adrenomedullin; ALDA, aldolase A; AMF, autocrine motility factor; CATHD, 
cathepsin D; EG-VEGF, endocrine gland-derived VEGF; ENG, endoglin; ET1, endothelin-1; ENO1, enolase 1; EPO, 
erythropoietin; FN1, fibronectin 1; GLUT1, glucose transporter 1; GLUT3, glucose transporter 3; GAPDH, glyceraldehyde-3-
P-dehydrogenase; HK1, hexokinase 1; HK2, hexokinase 2; IGF2, insulin-like growth-factor 2; KRT14, keratin 14; KRT18, 
keratin 18; KRT19, keratin 19; LDHA, lactate dehydrogenase A; LEP, leptin; MMP2, matrix metalloproteinase 2; PFKBF3, 6-
phosphofructo-2-kinase/fructose-2,6-biphosphatase-3; PFKL, phosphofructokinase L; PGK 1, phosphoglycerate kinase 1; 
TGF-α, transforming growth factor-α; TGF-β3, transforming growth factor-β3; TPI, triosephosphate isomerase; VEGF, 
vascular endothelial growth factor; UPAR, urokinase plasminogen activator receptor; VEGFR2, VEGF receptor-2; VIM, 
vimentin. 
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1.2.4. Epithelial-mesenchymal transition, hypoxia and acquisition 
of stem cell traits  
 
The epithelial-mesenchymal transition (EMT) is a multistep process characterized by 
loss of homotypic adhesion and cell polarity in which epithelial cells lose their epithelial 
characteristics and gain mesenchymal characteristics, such as motility and invasive 
properties (76). Type 3 or oncogenic EMT occurs in neoplastic cells that have previously 
undergone genetic and epigenetic changes, specifically in genes that favour clonal 
outgrowth and the development of localized tumours (77).  
As already described, tissue invasion and metastasis are prognostic indicators for 
risk of disease progression and reduced survival in bladder cancer, thus understanding 
EMT may provide insight for the development of novel tumour markers or new therapeutic 
strategies. In BC and other malignancies, the hallmarks of EMT are the loss of epithelial 
markers such as E-cadherin (calcium dependent transmembrane glycoproteins found at 
adherent junctions and responsible for cell-cell adhesion in epithelial tissues), the increase 
of matrix metalloproteinases (MMPs) involved in basement membrane degradation, the 
activation of the Rac/ Rho/Cdc42 small GTPase family implicated in cytoskeleton 
reorganization, and the nuclear translocation of transcription factors. The down-regulation 
of E-cadherin is associated with the release of β-catenin, which then migrates to the 
nucleus and activates WNT signalling, thereby resulting in the EMT and metastasis 
(78).There are multiple mechanisms resulting in E-cadherin mediated cell adhesion 
inactivation in cancer, such as “cadherin switching” in which the normal expression of E-
cadherin is replaced by the abnormal expression of P-cadherin and N-cadherin or N-
cadherin expression is increased and E-cadherin levels do not change significantly (79). 
However, one of the main mechanisms remains the transcriptional repression mediated by 
transcription factors such as ZEB-1, ZEB-2 (SIP1), Snail-1, Snail-2 (Slug), and TWIST1 as 
well as microRNAs (80,81). These transcriptional repressors result in epigenetic silencing 
of the E- cadherin promoter of E-cadherin-encoding gene (CDH1) by DNA 
hypermethylation. miR-200 family members participate in the EMT in a way that the loss of 
miR-200 expression leads to the accumulation of Zeb-1 and Zeb-2, which is sufficient to 
silence CDH1 and promote EMT and tumour invasion. In BC, expression of P-cadherin 
and N- cadherin, correlates with late stage, high grade disease and increased expression 
of MMP-9 was associated with a poor clinical outcome in patients with urothelial tumours. 
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Additionally, vimentin, an intermediate filament protein that induces epithelial cell changes, 
including their adoption of a mesenchymal shape and their increased motility, is 
characteristically up-regulated in cells undergoing EMT and was mainly detected in 
invasive BC (31% in MIBC vs. 7% in NMIBC) and was positively associated with tumour 
grade and stage (78). Moreover, EMT also seems to have a role in drug sensitivity of 
primary patient bladder tumours (44,45). 
Although both hypoxia and the EMT are separately considered as crucial events 
favouring the invasion and metastasis of many cancer cells, the two processes are long 
known to involve few common molecular mechanisms (83). Recently, an increasing 
amount of evidence demonstrates that alterations in microenvironmental oxygen levels 
and activation of hypoxic signalling through HIFs are important triggers and modulators of 
the EMT, which is now thought to take a key role as the convergence point between 
hypoxia and cancer (84). Under hypoxic conditions, the tumour microenvironment 
generates and sustains major EMT-triggering pathways for facilitating tumour growth and 
metastasis such as transforming growth factor (TGF) β and Notch signalling pathway as 
well as the nuclear factor kappa B (NFκB) pathway (85,86). At the early stages of tumour 
formation, TGFβ arrests cell proliferation and induces apoptosis. At later stages of 
tumorigenesis, TGFβ acts as a tumour promoter by increasing tumour cell proliferation, 
survival, motility and invasion probably by up-regulation of Snail and Slug that are potent 
initiators of the EMT in cancer cells (78). HIF-1α and TGFβ co-regulate gene products 
whose expression is increased as a result of the EMT process. Additionally, HIF-1α 
interacts with the Notch intracellular domain and increases its transcriptional activity. 
Moreover, the interplay between HIF-1α and Notch appears to be important for stem cell 
maintenance under hypoxia. Furthermore, NFκB is a key transcriptional activator of HIF-
1α, and basal NFκB activity is required for HIF-1α protein accumulation under hypoxia in 
cultured cells and in the livers and brains of hypoxic animals. Finally, there is growing 
experimental evidence that HIFs modulate the EMT by regulating the expression and 
activity of major transcription factors including those already referred TWIST, SNAIL, 
SLUG, SIP1 and ZEB1 (83).  
Up until now, EMT has been implicated in two of the most important processes 
responsible for cancer-related mortality: development of distant metastasis and acquisition 
of therapeutic resistance. Both of these processes may be linked, in turn, to a third: the 
generation by EMT of cancer cells with stem cell-like characteristics. As described before, 
hypoxia has the potential to regulate cell differentiation, which has led to the emergence of 
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a new paradigm that tumour hypoxia may facilitate the maintenance of cancer stem cell 
characteristics in a HIF-dependent manner and thus allow a tumour cell with self-renewal 
potential to accumulate a multitude of genetic and epigenetic changes over a long period 
of time in order to become increasingly aggressive and resistant (87,88). Within a tumour, 
stem-like cells reside in defined microenvironments termed “stem cell niches” and hypoxia 
may be an important feature of those microenvironments. HIF-2α is an upstream regulator 
of Pou5f1 (Oct4), which is one of the main transcription factors used to generate the first 
induced pluripotent stem cells (iPSCs). It has been shown that knock-down of HIF-2α but 
not HIF-1α, leads to a decrease in the expression of Oct4, Nanog and Sox2, which are 
important stem cells markers (89). 
In several models of cancer, the induction of EMT potentiates self-renewal and the 
acquisition of cancer stem-cell properties. Consequently, a common notion is that EMT 
may be a general feature of cancer stem or progenitor populations. This notion associates 
local invasiveness with the ability to colonize distant organs as expressions of two tightly 
interdependent gene programs borne by the same tumour cells. However, other models of 
neoplasia have found an inverse correlation between local invasiveness and the ability of 
tumour cells to colonize distant organs. This suggests a dichotomy between these two 
critical features of the metastatic process, possibly expressed by separate tumour cell 
subpopulations in which tumour cells that display a strong epithelial phenotype are 
endowed with the strongest capacity to survive in circulation and to establish distant 
metastases (76,90). 
It is important to note that EMT is usually not an irreversible transition, cells can 
return to their epithelial phenotype once they have reached the metastatic sites for re-
establishing barrier function and for enabling cell proliferation in a process called 
mesenchymal-epithelial transition (MET). Thus, in the absence of the EMT-inducing 
signals received from the ‘activated’ stroma, metastatic cancer cells might simply fall back 
to an epithelial state through an MET. For example, E-cadherin expression is re-induced in 
metastases, a change that is accompanied by the demethylation of the CDH1 promoter 
(77). However, sustained activation of EMT leads to progressive epigenetic alterations in 
cells, inducing heritable effects that maintain the mesenchymal state even after EMT-
initiating signals are no longer present. Hence, under certain conditions, EMTs can yield 
stable changes in the phenotype and thus lineage identity of cells (77). 
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Figure 4. Invasion of the basement membrane is the defining characteristic of epithelial cancers. A. Epithelial cells are 
normally constrained by cell–cell contacts and by the basement membrane (BM). B. Cancer cells produce proteases, 
including the urokinase-type plasminogen-activator receptor (uPAR) and matrix metalloproteinase-2 (MMP2), which digest 
the basement membrane/extracellular matrix (ECM). C. Degraded ECM is replaced by fibronectin and other ECM proteins 
that are recognized by integrins that are expressed on cancer cells. D. An epithelial-to-mesenchymal transformation occurs 
in which intermediate-filament production is switched from keratin subtypes, which are characteristic of fixed epithelial cells, 
to keratins and vimentin, which promote the fluid structure that is required for motility and which is also stimulated by 
expression of secreted factors such as autocrine motility factor (AMF) and transforming growth factor-α (TGF-α), and surface 
receptors such as the c-MET tyrosine kinase. HIF-1 target genes that regulate invasion are listed (75). 
 
1.3. Glycosylation and cancer 
 
1.3.1. General features of glycosylation 
 
 
 
Glycosylation is the most frequent, complex and plastic posttranslational modification 
(PTM) of membrane-bound and secreted proteins and results from a coordinated action of 
nucleotide sugar transporters, glycosyltransferases and glycosidases in the endoplasmatic 
reticulum and the Golgi apparatus. Glycans play a key role in protein folding, trafficking 
and stability and act as mediators of cell-cell adhesion, cell differentiation, migration, cell 
signaling pathways, immune recognition and host-pathogen interactions (91–94). 
Glycosylation increases the diversity of the proteome to a level unmatched by any other 
PTM, due to the diversity in sugar compositions, glycosidic linkages, chain length and 
substitution patterns. Glycosylation is also thought to be the most complex PTM due to the 
large number of enzymatic steps involved, along with the fact that unlike other cell 
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processes, such as transcription or translation, glycosylation is non-templated, and thus, 
all of these steps do not necessarily occur during every glycosylation event. On the other 
hand, despite all the heterogeneity and enzymes involved, glycosylation mechanisms are 
highly-ordered and normally individual enzyme activity is dependent upon the completion 
of the previous enzymatic reactions. As said before, this PTM is characterized by various 
glycosidic linkages, including N- , O- and C-linked glycosylation, glypiation (GPI anchor 
attachment) and phosphoglycosylation (95–99). Concerning the different types of 
glycosylation, they depend on multiple factors such as enzyme availability, amino acid 
sequence and protein conformation (100). 
Focusing on the most common types of glycosylation, two main classes of glycans 
can be found at the cell-surface, namely N-glycans and O-glycans. Although glycosylation 
has been so far characterized as a post-translational modification, N-glycosylation often 
occurs co-translationally during the translation and transport of proteins into the ER. N-
glycans are covalently attached to protein asparagine residues by N-glycosidic bonds, of 
which GlcNAcβ1-Asn is the most common. Precursor N-glycan synthesis begins on the 
cytosolic face of the ER and is further elongated after the structure is flipped into the ER 
lumen. In proteins, the candidates for receiving an N-glycan are called Asn-X-Ser/Thr 
“sequons”, with “X” being any amino acid residue except proline (92). Oligosaccharide 
transferase (OSTase) scans the nascent protein polypeptides for this consensus sequence 
and then transfers the precursor glycan (Glc3Man9GlcNac2-) from dolichol pyrophosphate 
to the Asn residue. To this point, all N-linked glycoproteins have the same precursor 
glycan structure. Glycan processing to diversify the glycans on individual glycoproteins 
occurs in the Golgi and combines both trimming and adding sugars to the structures in a 
step-wise fashion (101–103). Mature N-glycans chains can be modified by the action of 
fucosyl and sialyltransferases, yielding sialic acids, Lewis (Le) blood group related 
antigens (Lea, SLea, Lex, SLex, Leb and Ley) or ABO(H) blood group determinants as 
terminal structures. Other sugar modification may include phosphorylation, O-acetylation 
of sialic acids and O-sulfation of galactose and N-acetylglucosamine residues, thereby 
increasing the structural complexity of the glycome. 
N-glycosylation does not preclude the second most common type of glycosylation, 
O-glycosylation, from happening, as O-glycosylation commonly takes place on 
glycoproteins previously N-glycosylated in the ER. O-glycosylation occurs post-
translationally by covalently α-linking a GalNAc moiety from a sugar donor UDP-GalNAc to 
protein serine or threonine residues and is controlled by UDPGalNAc-polypeptide N-
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acetylgalactosaminyl- transferases (ppGalNAc-Ts). As opposed to N-glycosylation there is 
no consensus sequence for the activity of N-acetylgalactosamine transferase and following 
the first sugar addition a highly variable number of sugars are consecutively added to the 
growing glycan chain such as galactose, N-acetylglucosamine, fucose or sialic acid but not 
mannose, glucose or xylose residues. A second level of complexity in O-glycosylation is 
the processing of carbohydrate chains by other glycosyltransferases. After the first glycan 
(GalNAc) is added forming the Tn antigen, the core 1 structure is synthesised by Gal-
transferase (β(1-3)-galactosyltransferase, C1Gal-T1 or T-synthase) , which adds Gal to 
GalNAc. The core 1 structure may be also termed T antigen or Thomsen-Friedenreich 
antigen (Galβ1-3GalNAcα-O-Ser/Thr). Alternatively, Tn and T antigens can be sialylated 
by sialyltransferases forming the sialyl-Tn, sialyl-T and disialyl-T antigens and the 
formation of the sialyl-Tn antigen stops any further processing of the oligosaccharide 
chain. Core 1 may function as a precursor of other core structures (from core 2 to 8), by 
the addition of different monosaccharides, such as galactose, N-acetylgalactosamine, N-
acetylglucosamine and sialic acids. Furthermore, cores 1-4 are the most common in 
humans. The extension of core units provides a vast array of glycan structures, and is 
catalysed by N-β3/4-acetylglucosaminyltransferases (β3/4 Gn-Ts) and/or β3/4-
galactosyltransferases (β3/4 Gal-Ts), leading to the formation of side chains designated 
type-1 (Galβ1-3GlcNAc-R) and type-2 (Galβ1-4GlcNAc-R) chains. These chains present a 
ubiquitous expression, and therefore are widely expressed among epithelial tissues. 
Mature O-glycans may present terminal structures similar to the ones found in N-glycans 
(100).  
This type of glycosylation is particularly found and modulates the biological role of 
mucins, a family of high molecular weight glycoproteins rich in repetitive sequences of 
serine and threonine residues termed tandem repeat domains (VNTR), which are 
ubiquitously present in mucous secretions, on cell surfaces as transmembrane 
glycoproteins and in body fluids. Mucins that span the plasma membrane are known to be 
involved in signal transduction, to mediate cell-cell adhesion or to have an anti-adhesive 
function (104). Mucins have also been shown to have roles in fertilization and immune 
responses. Their presence shield the epithelial surfaces against physical and chemical 
damage and protects against infection by pathogens. The expression of mucin genes is 
regulated by a large number of cytokines and growth factors, differentiation factors and 
bacterial products. Recently, a precision mapping of human O-GalNAc glycoproteome has 
revealed over 6000 glycosites in more than 600 O-glycoproteins, the majority of which 
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were found at the cell surface (105), thereby greatly expanding the view of the O-
glycoproteome and its functional role. Of note, several intracellular proteins, including 
cytoplasmatic, mitochondrial and nuclear proteins, have also been found expressing this 
type of posttranslational modification. Despite the need for further analytical validation, 
these observations may suggest an up until now neglected role for O-GalNAc 
glycosylation in intracellular events (105). There are also several types of non-mucin O-
glycans, such as α-linked O-fucose, β-linked O-xylose, α-linked O-mannose, β-linked O-
GlcNAc, among others. O-glycosylation can also occur in the cytosol and nucleus to 
regulate gene expression or signal transduction through other glycosyltransferases. This 
nuclear O-glycosylation is performed by a single N-acetylglucosamine (GlcNAc) residue, 
and appears to perform a signalling role similar to protein phosphorylation. 
 
1.3.2. Alterations in glycosylation as biomarkers of cancer 
 
Aberrant glycosylation in cell surface glycolipids, membrane-associated and 
secreted glycoproteins occurs in essentially all types of human cancers, and many 
glycoepitopes constitute tumour-associated antigens. Those found in the surface of cancer 
cells are easily accessible to antibodies and lectins while those released to the peripheral 
circulation, either in secreted glycoproteins or by shedding from cell surfaces can be 
explored in various serological assays. Changes in some oligosaccharide structures 
associated with human cancer correlate with a precise stage of disease and their detection 
with lectins or monoclonal antibodies provide useful diagnostic or prognostic information, 
or both, and in many cases they contribute directly to cancer biology. A long-standing 
debate is whether aberrant glycosylation is a result or a cause of cancer. Many recent 
studies indicate that some, if not all, aberrant glycosylation is a result of initial oncogenic 
transformation, as well as a key event in induction of invasion and metastasis. Moreover, 
glycosylation promoting or inhibiting tumour cell invasion and metastasis is of crucial 
importance in current cancer research (106). Generally, the most frequently described 
cancer related changes in the pattern of glycosylation include the synthesis of highly 
branched and heavily sialylated glycans, the premature termination of biosynthesis, 
resulting in the expression of uncompleted forms, and the re-expression of glycosidic 
antigens of foetal type. In many cases the formation of these aberrant structures depends 
on altered regulation of one or more key glycosyltransferases (107).  
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As already described, cell-cell adhesion in epithelial tissues and tumour cells is 
mediated by E-cadherin in combination with α- and β-catenin and other cytoplasmic 
components, which link E-cadherin to the cytoskeleton. A decreased intra-tumour cell 
adhesion results in increased motility of tumour cells and increased metastatic potential. 
The type of N-glycosylation of E-cadherin modulates cadherin-dependent cell adhesion 
trough one of the most common forms of glycosylation aberration, namely the increased 
β1-6 branching of N-glycans in result of enhanced expression of GlcNAcT-V. Enhanced 
expression of GlcNAcT-III, another glycosyltransferase affecting N-glycan structure by 
catalysing the addiction of the bisecting GlcNAc branch, has also been reported in certain 
tumours and has the inverse effect. Enhanced GlcNAcT-V gene activity results in 
increased β1-6GlcNac antenna, to form multi-antennary structures without bisecting 
GlcNAc, and decreases cadherin activity. This reduces adhesion between tumour cells 
promoting metastasis. Additionally, the secreted form of GnT-V per se is angiogenic, which 
also promotes metastasis. On the other hand, overexpression of GlcNAcT-III reduces β1-
6GlcNac antenna, resulting in overall structural change, enhanced E-cadherin activity, and 
reduced malignancy (108). 
Among the most common structural features associated with cancer are the altered 
expression of terminal structures, which includes loss of ABO determinants by secretor 
individuals, changes in Lewis antigenic patterns and oversialylation. Moreover, the degree 
of A/B deletion is associated with the degree of metastasis or malignancy (109).  
The overall increase in cell-surface sialic acid content is also a tumour cell feature 
which reduces the attachment of metastatic tumour cells to the matrix and may help 
protect them from recognition by the alternative pathway of complement activation. 
Sialoglycoprotein patterns are not determined exclusively by the transcription of 
biosynthetic enzymes or the availability of target sequons, instead bulk metabolic flux 
through the sialic acid pathway has the ability to increase the abundance of certain 
sialoglycoproteins while having a minimal impact on others (110). Apart from the amount 
and linkage of sialic acids, there can also be significant changes in their modifications as 
will be exemplified latter. The changes in Lewis antigenic patterns mentioned above are 
related to over-sialylation of terminal structures, resulting in an over-expression of selectin-
ligands sialyl lewisa (SLea) and sialyl lewisx (SLex) antigens, which can be found in both N-
glycans and O-glycans as well as glycosphingolipids. These sLea and sLex antigens result 
from the O-3 sialylation of the Gal residue on Lea (Galβ(1-3)GlcNAc[Fucα(1-4)]) and Lex 
((Galβ(1-3)GlcNAc[Fucα(1-4)]) residues, respectively. The SLea and SLex, are expressed 
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in cancer cells, mimicking their normal expression on blood cells (monocytes and 
neutrophils) and also mimicking their potential for migration through binding to endothelial 
cell selectins, thus conferring a selective advantage for tumours cells interactions with 
endogenous selectins. The initial adhesion mediated by these molecules triggers 
activation of integrin molecules through the action of several cytokines and leads to 
integrin-mediated cell adhesion and extravasation of cancer cells. Moreover, cancer cells 
also produce humoral factors that facilitate E-selectin expression on endothelial cells, and 
specific alterations in the transcription of several glycosyltransferases such as ST3O, 
UGT1 and fucosyltransferase VII and sugar transporters in cancer has also been 
suggested to be involved in the induction of the selectin ligands on cancer cells (93,111–
114). Sialylated Lewis antigens can also be released to the bloodstream by malignant 
cells, thus, soluble forms of these antigens are also expressed in high amounts in the 
blood of many cancer patients. Based on these features, the serological evaluation of SLea 
is currently explored in the CA19-9 test for non-invasive assessment of tumour 
progression and metastatic spread (94).  
Also, minimal structural alterations in terminal motifs may significantly alter the 
biological behaviour of the glycans and be explored has biomarkers of disease. Namely, a 
glycan epitope that is very similar to SLex, the sialyl-6-sulfo Lewisx, was noticed to be 
preferentially expressed in normal epithelial cells compared to cancer cells. Essentially all 
genes involved in the synthesis of SLex are predicted to be the same as those involved in 
the synthesis of sialyl-6-sulfo Lewisx, except for the genes engaged in its sulfation. Thus, 
this finding supports the idea that the reduced expression of sialyl-6-sulfo Lewisx causes 
induction of SLex expression in cancers. Moreover, a structure very similar to SLea termed 
disialyl-Lewisa is preferentially expressed in non-malignant cells, and is useful as a marker 
for tissue injuries occurring in benign diseases. The structural difference between SLea 
and disialyl-Lewisa is the presence of one extra sialic acid residue attached to the C-6 
position of βGlcNAc in the carbohydrate structure of the latter glycan epitope. This implies 
that α-2-6 sialylation at the GlcNAc moiety is impaired in cancer cells compared to non-
malignant cells. This event has been associated with a significant decrease in the 
transcription of the sialyltransferase gene responsible for α2-6 sialylation of the βGlcNAc 
moiety in cancers compared to normal cells due to epigenetic silencing (24). 
Increased expression of galectins (especially galectin-3) has also been associated 
with tumour progression. Galectins are N-acetyllactosamine (Galβ1-4GlcNAc)-binding 
proteins that have either one or two carbohydrate reactive domains and form complexes 
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that cross-link glycoproteins dependent on their glycan structures and concentrations. 
They interact with glycoproteins in both extracellular and intracellular environments and 
regulate various biological phenomena, including cell growth, cell differentiation, cell 
adhesion, and apoptosis. A molecular significance for the correlation between increased 
galectin expression and tumour progression is proposed to be the interaction of galectins 
with poly-N-acetyllactosamines on matrix proteins such as laminin, which aids cellular 
invasion.  
Alterations in O-glycosylation pathways are also a common hallmark of malignant 
transformations, frequently amplified at the cell-surface as a result of the high number of 
O-glycosylation sites presented by mucins. Such events are particularly pronounced in 
adenocarcinomas, due to the overexpression of these molecules. Perhaps the most 
studied cancer-associated O-glycans result from a premature stop in the O-glycosylation 
of proteins, namely the Tn antigen (the simplest O-glycan), their sialylated counterpart 
sialyl-Tn (sTn; Neu5Ac2-6GalNAc-O-Ser/Thr ) and the T or core 1 antigen that results 
from the addition of a Gal residue to the Tn antigen (Galβ1-3GalNAc-Ser/Thr). These 
antigens have been classically termed simple mucin-type O-glycans reflecting their 
overexpression in cancer-associated mucins, and stem from the incapability of the cell 
glycosylation machinery to produce more elongated glycans (104). Namely, several 
reports attribute the expression of simple mucin-type O-glycans to a disorganisation of 
secretory pathway organelles (ER and Golgi) in cancer cells, and absence or altered 
expression and/or activity of glycosyltransferases responsible for the synthesis of glycan 
core structures (115). In particular, the overexpression of ST6GalNAc-I has been found to 
promote the premature sialylation of the Tn antigen and consequent formation of the STn 
antigen, thereby avoiding chain elongation in gastrointestinal tissues (116), breast cancer 
(117) and bladder cancer (15) models. Mutations on Cosmc, a molecular chaperone 
essential for T-synthase function has been found to promote the accumulation of Tn and 
STn antigens in neoplastic lesions, including colon cancer and melanoma-derived cells 
lines (118) as well as in breast carcinomas (119). 
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While hindered by extended glycosylation in healthy and benign tissues, simple 
mucin-type O-GalNAc glycans are uncovered in the majority of human carcinomas, 
particularly in advanced stages of the disease. The Tn, STn and T antigens have been 
associated with malignant cell phenotypes and disease progression, metastasis and poor 
prognosis in clinical settings for a variety of different solid tumours, in particular of 
gastrointestinal nature (116,120,121) but also breast (122,123), lung (124) and ovarian 
cancers (125) and its role as promoters of aggressive cell phenotypes confirmed in vitro 
(126,127). The fact that these simple glycans are absent, significantly under-expressed or 
restricted to some cell types in healthy tissues, makes them ideal diagnostic and 
therapeutic targets (128). Proteins carrying these glycans are often released from the cell-
surface and contribute to raised STn concentrations in serum (CA72-4 test) in gastric, 
colorectal and pancreatic carcinoma patients (129,130) as well as in gastric pre-cancerous 
lesions (131). The elevation of CA72-4 is considered to be useful as an independent 
prognostic factor in gastric cancer (132) and of tumour recurrence in gastric (133) and 
pancreatic cancers (134). Also, several monoclonal antibodies have been developed for 
STn as well as the therapeutic vaccine Theratope that, despite promising upfront results in 
pre-clinical and early stage clinical trials for advanced breast tumours (135–137), remains 
to be comprehensively accessed in clinical settings in other tumours (138). 
 
1.3.3. Glycosylation in BC 
 
Alterations in glycosylation of bladder tumours relate to the loss of ABO blood group 
determinants in advanced stage carcinomas of secretor individuals (the Se – secretor – 
locus dictates the capability of an individual to secrete glycoproteins carrying blood group 
antigens in saliva and other tissues) (139,140). Concomitantly, changes in Lewis antigens 
patterns, and the over-expression of simple mucin type O-GalNAc glycans have also been 
reported (141).  
The possibility that loss of the genetically predicted blood group antigens precedes 
the development of recurrent, invasive or metastatic cancer has been extensively 
explored. The ABO blood group system consists of terminal oligosaccharide antigens 
carried by glycoproteins or glycolipids in hematopoietic or epithelial cells. Their 
biosynthesis is presumed to be controlled by the ABO, Se, H, Le, and X gene loci, which 
code for specific glycosyltransferases. These enzymes add monosaccharides to 
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precursors in a sequential fashion in which the product of one glycosyltransferase 
becomes the substrate of the next acting glycosyltransferase. This complex relationship 
leads to genetic and structural polymorphisms. Studies have shown that loss of tissue 
ABH (O) antigens in the initial biopsy of bladder carcinomas is predictive of a much greater 
chance of subsequent invasion than in those tumours in which the ABH antigens are 
detectable (142). However, a significant number of patients whose initial tumours were 
reported as blood group antigen negative failed to develop an invasive tumour. It is 
possible that these conflicting results may, at least in part, be explained by differences in 
methodology or interpretation, or both. These antigens are present on normal bladder 
epithelium but not on some low-grade and early- stage papillary transitional cell 
carcinomas of the bladder. In bladder urothelium the most well examined change has been 
the deletion of blood group A antigens from A individuals and H antigen from O individuals. 
Moreover, it has been reported the disappearance of the activity of the A and B gene-
encoded transferases in bladder tumours from blood group A and B individuals which 
explains the deletion of these antigens in bladder tumours (143) . 
The A, B, H antigens have biosynthetic and structural similarities with the Lewis 
antigens, including the type 1 Lewisa and type 2 Lewisx antigens. Several authors have 
also associated the Lewisa expression patterns with malignant transformations in the 
bladder, others reported significantly lower expression of this antigen in healthy urothelium 
(6%), when compared to invasive tumours of the bladder (35%) (144,145). In agreement 
with this study, others have reported a high expression of Lewisa antigen in invasive 
bladder carcinomas (93%). Altogether, one can associate the expression of Lewisa antigen 
with a malignant phenotype of bladder tumour. Immunostaining of Lewisx antigen in the 
exfoliated cells of a single urine sample is a potentially useful diagnostic test, since up to 
90% of bladder tumours express Lewisx antigen (144). Moreover, apart from their 
diagnostic utility, the sialylated forms of Lewisx antigens have been closely linked to the 
invasive and metastatic potential of bladder cancer (146).The sialylated form of Lewisa, the 
SLea antigen, has been observed in bladder dysplasia, CIS, non-invasive and invasive 
carcinomas of the bladder (147). Nevertheless, no correlation was found with invasive or 
metastatic potential. 
The expression of β1-6 branched N-linked oligosaccharides and the GnT-V enzyme 
responsible by this structural alteration was closely related to low malignant potential in 
bladder cancer, a finding that could be applied to risk stratification (148). 
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As already stated, hyaluronic acid (HA) and its degrading enzyme hyaluronidase 
(HAase) are intricately involved in tumour growth and metastasis. HA is synthesized by the 
HA synthases HAS1, HAS2, and HAS3. HAS1 expression in tumour tissues is a predictor 
of bladder cancer recurrence and treatment failure. HA promotes tumour metastasis and is 
an accurate diagnostic marker for bladder cancer. Moreover, the measurement of HA and 
HAase (the HA-HA test) has been applied to the screening of bladder cancer. It has been 
shown recently that HAS1 regulates bladder cancer growth and progression by modulating 
HA synthesis and HA receptor levels (149).  
The galectin protein family was also implicated in bladder cancer. Galectin-1 mRNA 
levels were markedly increased in most high-grade bladder cancers compared with normal 
bladder or low-grade cancers. Galectin-3 mRNA levels were also increased in most 
tumours compared with normal urothelium, but levels were comparable among tumours of 
different histological grade. Moreover, galectin-7 expression may be related to the 
chemosensitivity of urothelial cancer (150). 
Glycosphingolipids (GSLs), including gangliosides (acidic glycosphingolipids which 
contain sialic acids), interact with specific membrane proteins, such as growth factor 
receptors, integrins, tetraspanins (TSPs), and non-receptor cytoplasmic kinases (e.g., Src 
family kinases and small G proteins), to form glycosynaptic microdomains controlling GSL-
dependent or -modulated cell adhesion, growth, and motility. The glycosphingolipid 
composition of human bladder cancer tissue has been assessed and the results have 
demonstrated that large amounts of ganglioside GM3 accumulate in superficial bladder 
tumours, compared with invasive bladder tumours and that exogenous GM3 inhibits the 
invasive potential of bladder tumour cells. Furthermore, the GM3 overexpression system 
was applied to bladder tumour therapy and exogenous GM3 inhibited bladder cancer cell 
invasion as well as locally injected GM3 (151). Additionally, GM3 synthase gene 
transfection had an antitumor effect on the murine bladder cancer MBT-2 cell line. It has 
also been reported that the expression of GM2, GM3, or GM2/GM3 complexes affect cell 
motility and growth in bladder cancer (152). 
Finally, increased levels of simple-mucin type O-GalNAc glycans have also been 
observed in bladder cancer. Several reports associate the presence of Tn and T antigens 
with recurrence and metastasis suggesting these antigens may be surrogate markers of 
profound cellular alterations (153,154). There is also growing evidences linking the 
overexpression of the sialyl-T antigen and ST3Gal.I, the enzyme responsible by T antigen 
sialylation, with bladder cancer aggressiveness and recurrence (155). Adding to these 
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findings, Ferreira et al. has recently demonstrated that over 70% of high-grade NMIBC and 
MIBC expressed the STn antigen, whereas 80% of low-grade NMIBC and the healthy 
urothelium do not. The STn antigen was mostly expressed by cells in non-proliferative 
tumour areas, known for their high resistance to cytostatic agents currently used to 
improve the overall survival of advanced stage bladder cancer patients. Studies in vitro 
have further demonstrated that this antigen plays an important role in bladder cancer cell 
migration and invasion trough mechanisms so far unexplored (15). Also, previous works of 
our group have demonstrated the presence of STn in metastized ganglia and distant 
metastasis, suggesting that the expression of STn may reflect on the mobility of cancer 
cells and the capability to metastasize.  
Other studies in STn-expressing bladder cancer cells shown that STn has the ability 
to down-regulate the anti-cancer immune-response through different mechanisms. First, it 
hinders the expression of MHC-II and co-stimulatory molecules by dendritic cells (DCs), 
resulting in impaired ability to present cancer-associated antigens to T cells and making 
DCs unresponsive to successive activation stimuli. Second, it hinders the expression of 
inflammatory, Th1-inducing cytokines in DCs, which may result in an attenuation of the 
Th1 microenvironment and reduced ability to activate and polarize T cells towards the Th1 
phenotype. Altogether, these results highlight the expression of STn by cancer cells as a 
crucial event in the establishment of the tolerogenic microenvironment which allows 
cancers to escape from the attack of innate and adaptive immunity (156).  
Despite the key role of the STn in bladder cancer progression and dissemination, to 
this date, the promoters leading its biosynthesis remain yet unknown. Nevertheless, 
preliminary data from our group is showing a correlation between the levels of STn and 
hypoxic marker HIF-1 in bladder tumours sections, suggesting that hypoxia might be the 
missing link responsible by STn expression in bladder cancer. More in depth studies are 
needed to validate these preliminary observations. 
 
1.3.4. Hypoxic regulation of glycosylation in cancer 
 
Glycosylation is kinetically regulated by dynamically changing the portfolio of 
glycosyltransferases, nucleotide sugars, and nucleotide sugar transporters, which together 
form a part of what is currently referred to as the “Glycan cycle”. Hypoxic conditions 
dramatically change gene expression profiles, by activating HIF-1, which mediates 
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adaptive cellular responses, which have been extensively addressed in the previous 
section. As already mentioned, HIF-1α induces the expression of glucose transporters and 
various types of glycolytic enzymes, leading to shifts in glucose metabolic patterns. This 
fact strongly suggests that hypoxic conditions are an important factor modulating various 
nucleotide sugar biosynthetic pathways. Hypoxia-induced glycosyltransferases and 
nucleotide sugar transporters have also been shown to modulate glycosylation patterns 
that are part of the mechanism associated with cancer metastasis. For example, hypoxia 
has an impact in the UDP-GalNAc cycle, as well as in the N-
Acetylglucosaminyltransferases V (GnT-V) activity by reducing the activity of a portion of 
the GlcNAc cycle, including intracellular UDP-GlcNAc levels and GnT-V activity in a HIF-
1α-dependent manner (157). Hypoxia also influences galactose metabolism as exemplified 
by enhanced expression of genes involved in transport, phosphorylation, and transfer of 
galactose, and this seems to trigger drastic alteration of other monosaccharides including 
sialic acid (24). The influence of hypoxia on the metabolism of monosaccharides other 
than glucose, however, is not fully elucidated. 
Hypoxia increases the levels of cell surface SLex and Slea determinants in colon 
cancer cell lines, as well as the transcription of fucosyltransferase VII (FUT7), 
sialyltransferase ST3Gal-I and UDP-Gal transporter 1 in colon cancer tissues, which are 
involved in the synthesis of the carbohydrate ligands of endothelial E-selectin (157–159). 
Some qualitative changes of glycans are also induced by tumour hypoxia. For example, a 
part of the sialic acid residues in glycans is replaced by N-glycolyl sialic acid in cancers, 
while normal glycans usually carry N-acetyl sialic acid residues. This turned out to be due 
to induction of a gene for sialic acid transporter, Sialin, in cancers by tumour hypoxia. For 
instance, such cancer cells will frequently express N-glycolyl-SLea and N-glycolyl-SLex 
(24). 
Among various kinds of glycosaminoglycans (GAGs), hyaluronic acid (HA) and its 
degrading enzyme hyaluronidase (HAase) are intricately involved in tumour growth and 
metastasis. Metabolism of hyaluronan is also markedly influenced by hypoxia. Hyaluronan 
serves as a specific ligand for CD44, and the cell adhesion mediated by the CD44⁄ 
hyaluronan interaction is heavily involved in cancer cell motility (24). Tumour hypoxia also 
leads to expression of useful glycolipid tumour markers, such as gangliosides having N- 
glycolyl sialic acid. Moreover, hypoxia affects not only the glycan moiety of glycolipids, but 
also their ceramide moiety (160). Nevertheless, despite these findings, no study has 
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addressed the influence of hypoxia in the expression of simple mucin-type O-GalNAc 
glycans in cancer.
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II. Background, Aims and Experimental outline 
 
Muscle invasive bladder cancer (MIBC) is considered a neglected neoplasia, 
nevertheless, over 54,000 deaths have been reported in Europe and around 165,100 
deaths worldwide in 2012, placing it amongst the deadliest genitourinary cancers (161). 
Cisplatin-based regimens are the only available therapeutics for invasive and metastatic 
cases, nevertheless, due to treatment failure, the five-year overall survival does not 
exceed 25% and many patients die prematurely from adverse drug reactions (2), urging for 
effective and safe targeted therapeutics.  
Even though conventional chemotherapy is efficient against highly proliferative 
malignant cells that form the tumour bulk, non-proliferative tumour areas, characterized by 
high hypoxia, harbour chemoresistant clones responsible by disease relapse, progression 
and dissemination. Preliminary findings from our group suggest that these areas express 
the STn antigen, which stems from a premature stop in protein glycosylation. This epitope 
has been found to favour disease dissemination and is also responsible by generating 
distinct protein signatures at the cell-surface, providing means to target aggressive cells. 
Nevertheless, the association between these STn expression and hypoxia remain yet to 
be elucidated.  
In the present work, hypoxia and STn are the main targets explored, especially 
because changes in the glycosylation of cell-surface and growth under oxygen deficiency 
(hypoxia) are salient features of solid tumours that often correlate with advanced stages of 
malignancy such as invasion and metastasis. As shown by several studies, hypoxia 
induces a wide range of biological changes, such as decreased cell proliferation, 
increased expression of drug-resistance genes, selection of apoptosis-resistant clones, 
facilitation of tumour invasion and metastasis, reduced expression of DNA repair genes, 
and increased genomic instability. These mechanisms undoubtedly contribute to the 
evolution of malignant tumour cells. However, it remains to be fully understood why 
hypoxic tumour cells tend to be more aggressive and more resistant to treatment than non-
hypoxic tumour cells within the same tumour, despite their similar genetic background. 
Furthermore, there is a lack of specific hypoxia-associated cell-surface biomarkers to 
guide therapeutics to these cell.  
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Based on this background, the present work aims to explore a possible association 
between STn expression and hypoxia, envisaging theragnostic biomarkers capable of 
improving bladder cancer overall survival.  
The project experimental outline includes the characterization of the effect of hypoxia 
on three bladder cancer cell lines with different molecular and genetic profiles regarding 
the activation of stem-cell and/or epithelial-to-mesenchymal transition programs, degree of 
proliferation, invasion capacity and STn expression, followed by validation in human 
tumour samples. Studies including the hypoxia-mimetic Deferoxamine Mesilate that 
stabilizes HIF-1α through the inhibition of Prolyl Hydroxylases (PHDs) activity by the 
chelation of Fe2+, will also be included to disclose HIF-1-mediated alterations. The 
generated information is regarded of primary importance to expand the knowledge about 
the clinical relevance of the STn antigen in bladder cancer and create the rationale for a 
STn-based therapy. 
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III. Materials and Methods 
 
3.1. Cell Lines 
 
This study was conducted on three urinary bladder cancer cell models, namely T24, 
5637 and HT1376 comprising the main genetic alterations commonly found in human 
urinary bladder cancer (UBC), which allows for the study of the most representative human 
bladder tumours. The accumulated data have shown that FGFR3 mutations are 
characteristic for low grade and low stage tumours whereas p53 and RB1 mutations are 
characteristic for invasive tumours. This has led to the suggestion that UBC develop 
through at least two molecular pathways, one related to FGFR3 and other related to p53 
and RB1 alterations (162). The cell lines used have different histological origins, the 5637 
cell line is derived from a grade II carcinoma, the HT1376 cell line from a grade III 
carcinoma and the T24 cell line from a transitional cell carcinoma (TCC). 5637 and 
HT1376 represent the E2F3/RB1 pathway with loss of one copy of RB1 and mutation of 
the remaining copy. Additionally, HT1376 exhibit deletion of PTEN gene and no alteration 
of PIK3CA, which in combination with the inactivation of p53 grants a more invasive and 
metastatic potential to this cell line. In contrast, the 5637 cell line does not present any loss 
of PTEN and loses PIK3CA gene, which gives it a less-invasive phenotype. The T24 cell 
line belongs to the alternative pathway of FGFR3/CCND1 by presenting a mutated HRAS 
and over-represented CCND1 (cyclin D1) (163). 
 
3.2. Cell culture conditions 
 
Cells were cultured in RPMI Medium 1640 (1X) + GlutaMAXTM-I (Gibco ®; Life 
Technologies) supplemented with 10% heat-inactivated FBS (Gibco ® Life Technologies) 
and 1% Pen Strep (10,000 Units/mL Penicilin, 10,000 µg/mL Streptomycin) (Gibco ® Life 
Technologies). Cell lines were cultured as a monolayer at 37 ºC in a 5% CO2 humidified 
atmosphere (normoxia), and were routinely subcultured after trypsinization.  
The cells were also grown under hypoxic atmosphere for 6, 24, 48 and 72 hours (as 
further indicated) in a BINDER C 150 incubator with 0.1% O2, 5% CO2 and the balance N2. 
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Additionally, cells were exposed to 500 µM Deferoxamine Mesilate CRS (DFX, Sigma-
Aldrich) to stabilize HIF-1α. All experiments were performed at 70-80% of cell confluence. 
 
3.3. L-Lactate assay 
 
A fluorometric L-Lactate assay kit (Abcam) was used to determine the concentration 
of the intermediary metabolism product L-Lactate in culture media. Lactate is produced in 
proliferating cells under anaerobic conditions, with L-lactate being the major stereo-isomer 
formed. In Abcam’s L–Lactate Assay Kit, lactate is oxidized by lactate dehydrogenase to 
generate a product which interacts with a probe producing color (570 nm) and 
fluorescence (at Ex/Em= 535/587nm). The reaction product fluorescence was measured at 
Ex/Em=535/590nm in a microplate reader (SynergyTM Mx, BioTek).  
 
3.4. Cell Proliferation Assay 
 
A colorimetric BrdU cell proliferation ELISA kit (ab126556 Abcam) was used to 
estimate cell proliferation. The test allows a quantitative measurement of the incorporation 
of Bromodeoxyuridine (5-bromo-2'-deoxyuridine, BrdU), a synthetic nucleoside analogue 
to thymidine, into newly synthesized DNA of actively proliferating cells. Briefly, T24 
(0.35x105 cells/mL), 5637 (0.15x105 cells/mL) and HT1376 (0.25x105 cells/mL) cells were 
cultured in 96 well plates and BrdU was added to the wells during the final 24 hours of 
culture. To enable antibody binding to incorporated BrdU, cells were fixed, permeabilized 
and the DNA denatured. This was all done in one step by treatment with a kit provided 
Fixing Solution. Subsequently, the anti-BrdU monoclonal antibody was pipetted into the 
wells and allowed to incubate for one hour, binding to any incorporated BrdU. Unbound 
antibody was washed and horseradish peroxidase-conjugated goat anti-mouse antibody 
was then added. The horseradish peroxidase catalysed the conversion of the chromogenic 
substrate tetra-methylbenzidine (TMB) from a colourless solution to a blue solution (or 
yellow after the addition of stopping reagent), the intensity of which is proportional to the 
amount of incorporated BrdU in the cells. The coloured reaction product was quantified 
using a single absorbance read at 450 nm by a microplate reader (SynergyTM Mx, 
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BioTek) allowing the assessment of the population of cells which are actively synthesizing 
DNA.  
 
3.5. Cell Invasion Assay 
 
Invasion assays were performed using BD BioCoat MatrigelTM invasion chambers, 
comprised by an 8 µm diameter pore size filter coated with a thin layer of Matrigel. Prior to 
each experiment, filters were re-hydrated in serum-free RPMI medium for 1 h at 37 ºC. 
After detachment of confluent cells by trypsinization, cells were suspended in complete 
culture medium, counted and seeded on the upper side of the matrigel-coated filter at a 
density of 5x104 cells/ well. After incubation for 24h at 37 ºC under normoxic or hypoxic 
conditions, invasive cells were fixed with 4% Paraformaldehyde and non-invading cells, 
present on the upper side, were completely removed, to facilitate analysis. Cells that 
invaded the underside of the filters were mounted in Vectashield Mounting Medium with 
DAPI (Vectashiels®, Vector Laboratories), and visualized through a Leica DM2000 
fluorescence microscope (Leica Microsystems). Invasive cells were scored in at least 12 
microscopic fields (20x objective). 
 
3.6. Flow Cytometry analysis 
 
STn expression was determined by flow-cytometry. Approximately 106 cells/ml were 
seeded in 6-well plates and allowed to adhere for 24h. Subsequently, the medium was 
removed and the cells were repeatedly washed with PBS and dissociated into single-cell 
suspensions with Versene 1:5000 (1X) (Gibco) at 4 ºC, followed by filtration using a 70 µm 
Nylon cell strainer (BD Falcon). Detached cells were fixed with 4% Paraformaldehyde, 
suspended in 500 µL PBS and the anti-STn primary antibody was used according with 
table I indications. Finally, the cells were incubated with polyclonal rabbit anti-mouse 
Immunoglobulins/FITC (1:84) secondary antibody. After being washed, the cells were 
analysed by flow cytometry in a BeckMan Coulter FC500 Cytometer. Each independent 
experiment was performed in triplicate. 
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3.7. Neuraminidase treatments 
 
Whole cells and protein extracts previously digested with -neuraminidase were 
used as sialyl-Tn negative controls in flow cytometry and western blot analysis, 
respectively. Briefly, for flow cytometry analysis, cells were detached with Versene, 
filtered, suspended in RPMI Medium 1640 (1X) + GlutaMAXTM-I, and treated with 10 
U/mL -neuraminidase from Clostridium perfringens (Sigma) for 90 minutes at 37 ºC with 
frequent medium resuspension. For western blot, glycoproteins immobilized in 
nitrocellulose membranes were treated with 0.25 U/mL Neuraminidase for 2h at 37 ºC prior 
to probing with primary and secondary antibodies. 
 
3.8. Gelatin Zymography 
 
Gelatin zymography was performed to determine the activity of the matrix 
metalloproteinases MMP-2 and MMP-9. Proteins (15 µg/ lane) from conditioned media 
were separated on 10% polyacrylamide zymogram gels with 0.1% gelatin (MERCK) as a 
substrate. After electrophoresis, gels were incubated in 2% Triton X-100 (Sigma) in 
deionized water for protein renaturation, with gentle agitation for 30 minutes at room 
temperature. Subsequently, gels were incubated in MMP substrate buffer [50 mM Tris-
HCl, pH 7.5; 10 mM CaCl2] overnight with gentle shaking at 37 ºC. The gels were finally 
stained with filtered Coomassie blue solution (Sigma) for 30 minutes and then washed with 
deionized water until the adequate resolution was obtained. Gelatinolytic bands were 
observed as white areas against the blue background, and the intensity of the bands was 
evaluated using the Quantity One Software. 
 
3.9. Western Blot 
 
The expression of hypoxic biomarkers HIF-1, CA IX and cancer-associated 
carbohydrate antigen STn were evaluated by western blot. Proteins were isolated from 
whole cells in cell lysis Rippa buffer (20mM Tris [pH=7.5], 150mM NaCl, 1% Triton-X100, 
1% NP-40) containing protease and phosphatase inhibitor cocktail (HaltTM Protease & 
Phosphatase Inhibitor Cocktail; Thermo Scientific).The protein content was estimated 
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using DC Protein Assay (Bio-Rad) and then separated by SDS–PAGE under reducing 
conditions and transferred onto 0.45 µm nitrocellulose membranes (GE Healthcare). HIF-
1α, CA IX, STn, TB-α and GAPDH membranes were blocked with Carbo-Free Blocking 
Solution 1X (Vector Laboratories) for 1h at room temperature and incubated according 
with table I. After a washing procedure, membranes were incubated with the respective 
secondary antibody according with table I. After final washing, the bound antibodies were 
revealed by chemiluminescence using either the WesterBrightTM Sirius Kit (advansta) or 
the Amersham ECL Prime Western Blotting Detection Reagent kit (GE Healthcare) or 
Amersham ECL Western Blotting Detection Reagents (GE Healthcare), depending on the 
amount of epitope available. 
 
 Table I.- Primary and secondary antibody specification 
 
 
 
Method Primary Antibody Secundary antibody Incubation Conditions
Primary Ab: Dilution 1:250, 4 ⁰C 
overnigh
Secunday Ab: Dlilution 1:70.000, 
Room Temperature, 30 minutes
Primary Ab: Dilution, 1:2000 
Room Temperature, 30 minutes
Secundary Ab: Dilution 1: 
70.000, Room Temperature, 30 
minutes
Primary Ab:Dilution 1: 15.000, 
Room Temperature, 30 minutes
Secundary Ab: Dilution 1: 
70.000, Room Temperature, 30 
minutes
Primary Ab: Dilution 1:1000, 
Room temperature, 30 minutes
Secundary Ab: Dilution 
1:130.000, Room Temperature, 
30 minutes
Primary Ab: Dilution 1:5, Room 
Temperature, 30 minutes
Secundary Ab: Dilution 
1:130.000, Room Temperature, 
30 minutes
Primary Ab:  30 µl/106 cells, 
Room Temperature, 30 minutes
Secondary Ab:   6 µl/106 cells,  
Room temperature in the dark, 15 
minutes
Polyclonal anti-Mouse whole 
IgG affinity-Purified secondary 
antibody (Jackson 
ImmunoResearch)
western Blot
Flow Cytometry
Mouse Monoclonal [TKH2] 
to STn in culture 
supernatant
Polyclonal Rabbit Anti-Mouse 
Immunoglobulins/FITC (1:84)
Mouse monoclonal 
[16H4L13] to HIF-1-alpha 
(invitrogen)
Polyclonal anti-Mouse whole 
IgG affinity-Purified secondary 
antibody (Jackson 
ImmunoResearch)
Polyclonal anti-Mouse whole 
IgG affinity-Purified secondary 
antibody (Jackson 
ImmunoResearch)
Polyclonal anti-Mouse whole 
IgG affinity-Purified secondary 
antibody (Jackson 
ImmunoResearch)
Mouse monoclonal [2D3] 
to Carbonic Anhydrase IX 
(abcam)
Mouse monoclonal [B-5-1-
2] to alpha-Tubulin (Sigma)
Rabbit Polyclonal [FL-335] 
to GAPDH (Santa Cruz 
Biotechnology)
Polyclonal Peroxidase-
AffiniPure Goat Anti-Rabbit IgG 
(H+L) secondary antibody 
(Jackson ImmunoResearch)
Mouse Monoclonal [TKH2] 
to STn in culture 
supernatant
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3.10. Gene expression measurements 
 
Total RNA from cultured cells was isolated using TriPure isolation Reagent (Roche). 
The RNA quantity and its purity were determined using a NanoDrop ND-1000 
Spectrophotometer (NanoDrop Technologies, Inc). The cDNA was obtained through 
reverse transcriptase reaction using a High-Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems, Foster City, CA, USA). Reverse transcriptase reaction contained a 
total volume of 60 μL reaction mix with: 30 μL of master mix containing 1x RT Buffer, 4 mM 
of total dNTPs, 150 U MultiScribe Reverse Transcriptase Enzyme (Applied Biosystems, 
Foster City, CA, USA) and 30 μL (200 ng/ µl) of RNA sample. The amplification conditions 
were the following: 25 ºC for 10 minutes (min), 37 ºC for 120 min. and RT inactivation at 85 
ºC for 5 min. All reverse transcriptase reactions included two no-template controls (double 
distilled water replacing template RNA was used as negative controls). The products were 
amplified in a Mycycler Thermal cycler (Bio-Rad). 
The expression levels of a panel of 21 genes, including 3 reference genes were 
assessed by quantitative polymerase chain reaction (qPCR) on an StepOnePlus™ Real-
Time PCR System (Applied Biosystems, Foster City, CA, USA) with a 10 μL final volume 
mixture containing 1x TaqMan® Universal PCR Master Mix II (Applied Biosystems, Foster 
City, CA, USA), TaqMan® Gene Expression Assays (Applied Biosystems, Foster City, CA, 
USA) (Table II) and cDNA. Thermal cycling conditions were: 10 min. at 95 °C followed by 
45 cycles of 15 seconds (sec.) at 95 °C and 1 min. at 60 °C. All reactions were run in 
duplicate. During the cDNA exponential amplification the product formation was 
proportional to the fluorescence emission resulting from the TaqMan probe degradation 
(van der Velden et al., 2003). The mRNA levels were normalized for the expression of 
GAPDH, which was taken as a suitable endogenous control, once it was the most stable of 
the 3 evaluated reference genes. The relative mRNA levels were calculated by adapting 
the 2-ΔΔCt formula, according to the method described by Livak (164). 
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Table II - TaqMan Gene Expression Assays references used to assess transcript 
levels for the 24 selected genes 
 
  
 
 
 
 
 
 
 
 
 
3.11. Analysis of HIF-1α, CA IX, STn in bladder tumours 
 
Formalin-fixed, paraffin embedded (FFPE) tissue sections were screened for HIF-1, 
CA IX and STn by immunohistochemistry using the avidin/biotin peroxidase method. 
Briefly, 3 µm sections were deparaffinised with xylene, rehydrated with graded ethanol 
series, microwaved for 15 min in Antigen Unmasking Solution, high pH (Vector 
TaqMan Gene Expression 
Assay reference
NANOG Hs04260366_g1
LIN28A Hs01552405_g1
OCT-4 (POU5F1) Hs04260367_g1
KLF9 Hs00230918_m1
KLF4 Hs00358837_g1
SOX2 Hs01053049_s1
CDH1 Hs01023894_m1
DSP Hs00950591_m1
EpCAM Hs00901885_m1
FN1 Hs00365052_m1
CDH2 Hs00983056_m1
VIM Hs00185584_m1
Extracellular matrix synthesis and 
promotion of changes to cell shape
SNAI1 Hs00195591_m1
SNAI2 Hs00950344_m1
TWIST1 Hs01675818_s1
TWIST2 Hs00382379_m1
ZEB1 Hs01566410_m1
ZEB2 Hs00207691_m1
RUNX1 Hs01021971_m1
RUNX2 Hs01047973_m1
GAPDH Hs03929097_g1
HPRT Hs99999909_m1
ActB Hs99999903_m1
EMT
Housekeeping genes
Self-renewal and stemness
Epithelial phenotype
Mesenchymal phenotype
Hs00234160_m1SPARC
Cell function Gene
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Laboratories) and exposed to 3% hydrogen peroxide for 20 min. The expression of STn 
was then evaluated using anti-STn mouse monoclonal antibody, clone TKH2, 1:5 
overnight at 4 ºC, that identifies both single and clustered STn residues, whereas CA IX 
was identified using monoclonal mouse anti-human CA IX antibody (abcam),clone 2D3, 
1:100 1h at room temperature. The expression of HIF-1α was evaluated using monoclonal 
rabbit anti-human HIF-1α (Invitrogen), clone 16H4L13, 1:75 overnight at 37 ⁰C. After 
blockage with BSA (5% in PBS), the antigens were identified with Vectastain Elite ABC 
peroxidase kit (Vector Laboratories) followed by incubation with 3,3-diaminobenzidine 
tetrahydrochloride (DAB, Dako). Finally, the slides were counterstained with haematoxylin 
for 1 min. A semi-quantitative approach was established to score the 
immunohistochemical labelling based on the intensity of staining and the percentage of 
cells that stained positively. Both the percentage of positive tumour cells and the staining 
intensity were taken into account. The percentage of positive cells was rated as follows: 0 
points, no expression; 1 point, < 10% positive tumour cells; 2 points, 11–50% positive 
cells; 3 points, 51–80% positive cells; and 4 points, > 81% positive cells. The staining 
intensity was rated as follows: 1 point, weak intensity; 2 points, moderate intensity; and 3 
points, strong intensity. According to the overall score resulting from the arithmetic sum of 
these variables, the tumours were classified into four groups: absent nuclear 
immunostaining (0 points), < 10% positive cells, regardless of intensity (1-2); weak nuclear 
immunostaining (3); moderate nuclear immunostaining (4-5); and strong nuclear 
immunostaining (6-7). For statistical reasons, tumours were then scored according to a 
two-scale system: low reactivity denoting tumours with absent or weak nuclear 
immunostaining (0-3 points) and high reactivity denoting tumours with moderate to strong 
nuclear reactivity (4-7 points). According to the criteria defined by Ferreira et al., the 
tumours were considered positive for the STn antigen whenever reactivity was observed 
(15). 
 
3.12.  Statistical Analysis 
 
Statistical analysis was performed with IBM Statistical Package for Social Sciences-
SPSS for Windows (versions 20.0). T-student test was used to compare mean values with 
a 95% confidence interval. Chi-square analysis was used to compare categorical 
variables.   
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IV. Results and Discussion 
 
Muscle invasive bladder cancer is a highly aggressive malignancy characterized by 
decreased overall survival and poor response to chemotherapy, urging the identification of 
novel biomarkers with theragnostic potential. Preliminary observations in clinical samples 
(Ferreira et al., unpublished results) suggested that hypoxic conditions may promote the 
overexpression of proteins presenting the cancer-associated carbohydrate antigen sialyl-
Tn at the cell-surface, which has been found to enhance cell invasion capability and 
immune tolerance in vitro. Furthermore, the overexpression of specific cancer-related 
glycoproteins associated with aberrant glycosylation by STn has been shown to generate 
unique protein signatures at the cell-surface, providing means to selectively target 
aggressive cells (15,120,165). Despite these observations, the association between 
hypoxia and STn warrants validation. 
In the present work we assessed how hypoxia modulates proliferation, invasion, 
proteolytic capacity, as well as STn expression and the activation of stem-cell and/or 
epithelial-to-mesenchymal transition genetic programs in three genetically and molecularly 
distinct bladder cancer cell lines. HIF-1α, CA IX and STn expression was further validated 
in clinical samples. Moreover, HIF-1α-mediated alterations was disclosed using the 
hypoxia-mimetic DFX that stabilizes HIF-1α through the inhibition of Prolyl Hydroxylases 
(PHDs) activity by the chelation of Fe2+. 
 
4.1. Hypoxic response 
 
The first part of the study was devoted to assessing the hypoxic biomarkers HIF-1α 
and CA IX in the three cell lines over time, under hypoxic conditions (0.1% O2) and using 
the hypoxia mimetic DFX (500 µM), envisaging the optimization of the exposure time for 
further analysis. As previously described, HIF-1α is ubiquitously expressed by human cells 
and is an essential transcription factor for the transcription of CA9 gene and expression of 
CA IX protein. In experiments conducted in normoxia in the presence of DFX, the 
compound stabilizes HIF-1α through the inhibition of Prolyl Hydroxylases (PHDs) activity 
by the chelation of Fe2+, which is required for enzymatic activity, thereby mimicking 
hypoxic conditions. The inhibition of this enzyme, predominantly localized in the cytoplasm 
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where it plays a pivotal role in targeting HIF-1 for proteasomal degradation, was used in 
an attempt to highlight HIF-1-mediated events. 
Western blot data showed HIF-1α protein has two bands at approximately 92 and 
110 kDa (Figure 5A). The two bands for HIF-1α may result from post-translational 
modifications, splice variants or isorforms or multimer formation. Recent studies suggest 
that phosphorylation of HIF-1α by mitogen-activated protein (MAP) kinases is a common 
modification that increases its transcriptional activity independently of the effects of 
hypoxia, but the site(s) of phosphorylation and the mechanism by which transcriptional 
activity is enhanced have not been established yet (166). Additionally, splice variants of 
HIF-1α created by alternative splicing of the same gene, lacking several exons or 
displaying different exons than the wild type protein have already been reported and also 
may account for the two bands pattern for HIF-1α protein (167). Some of these isoforms 
encode cytoplasmic HIF-1α protein or proteins with altered transcriptional activity 
compared to the wild type protein. Regarding the N-terminal domain, two HIF-1α isoforms 
with different first exons have been identified: HIF1α1.2, a protein with a different first and 
second exons which is 59 amino acids shorter than wild type HIF-1α and encodes a 
cytoplasmic protein specifically expressed in the human testis (168); HIF1α1.3, which is 
present in activated T-lymphocytes and encodes a functional protein with weaker 
transcriptional activity that the wild type protein (169). At the C-terminal domain, isoforms 
lacking either exon 12 (170) or exons 11 and 12 (171) have been reported. Both isoforms 
have been shown to be stable cytoplasmic proteins and inhibit the function of full length 
HIF-1α. Another shorter HIF-1α isoform lacking exon 14 has also been reported (172). 
This isoform was shown to be 3-fold less active than full-length HIF1α. Furthermore, 
multimers may also contribute to this feature. Although multimers are usually prevented in 
reducing conditions, strong interactions can result in the appearance of higher bands. 
Altogether, post-translation modifications, splice variants and multimer formation contribute 
to the two bands pattern, and for quantification purposes the sum of the two consecutive 
bands was taken into account. The identification of the proteins in these bands by mass 
spectrometry should, in the future, allow confirming these hypotheses. The CA IX and TB-
α proteins appear in a single band pattern and have observed band sizes of 55 kDa and 
50 kDa, respectively (Figure 5A).  
Figure 5B shows that for T24 and 5637 cell lines, HIF-1α expression is higher at 24h, 
while for HT1376 cell line it is significantly increased at 6h in hypoxia and DFX conditions 
in relation to normoxia. The CA IX proteins follow the same tendency as HIF-1α (Figure 
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5B), in accordance with the fact that the transcription of this protein is strongly regulated by 
HIF-1. An increase in the exposure time of T24 and 5637 cells to hypoxia and DFX (48 
and 72h) results in a decrease in HIF-1 and CA IX protein levels. Such differences may 
reflect a response shift from acute hypoxia (≤ 24h) to longer-term or chronic hypoxia (> 
24h), which has been described to affect the transcription and translation of several 
proteins that might indirectly influence the expression of these markers (22). In addition, 
miRNAs may also directly influence HIF-1α responses to prolonged hypoxia. As part of the 
RNA-induced silencing complex (RISC), miRNAs negatively regulate gene transcription by 
annealing to the 3′ untranslated region of specific mRNA targets to repress translation, 
enhance mRNA degradation, or both (26,173). Hypoxia initially induces increased 
expression of HIF-1α, but during sustained hypoxia, the amount of HIF-1α mRNA is 
reduced. Instead, there is considerable overexpression of the HIF-1α natural antisense 
transcript (aHIF), which encodes the antisense template of the 3’-untranslated region of 
HIF-1α mRNA. This represents a negative feedback loop, in which aHIF inhibits the 
translation of HIF-1α mRNA after chronic hypoxia, clarifying the pattern observed 
(174,175). Furthermore, hypoxia has been shown to induce the expression of a number of 
other miRNAs, which have been termed “hypoxamirs” that regulate HIF-1α expression 
(17,21,105,106,176) 
Finally, the molecular differences observed between cell lines overtime might be 
explained by different genetic characteristics of each cell line. In tumour cells, loss of p53 
activity results in increased HIF-1α expression and increased transcription of downstream 
target genes such as CA IX. Furthermore, PTEN negatively regulates the PI3K pathway 
and, therefore, loss of PTEN activity leads to increased HIF-1α expression. So, PTEN 
mutations might promote tumour growth by synergistically promoting HIF-mediated 
responses (20). In HT1376 cells, PTEN gene is deleted which in combination with the 
inactivation of p53 potentiates expression of HIF-1α. This particular features may explain 
the reason why HT1376 cell line shows significant levels of HIF-1α protein after only 6h of 
exposure to hypoxic conditions in comparison with T24 and 5637 under the same 
microenvironmental challenge. 
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Figure 5. Urinary bladder cancer cell lines exposed to hypoxia and hypoxia mimetic DFX show differential expression of 
hypoxia markers over time. All cell lines were cultures for 24h before exposure to any experimental conditions. A. Western 
Blot analysis of HIF-1α and CA IX proteins, 24h (T24 and 5637 cell lines) and 6h (HT1376 cell line) after treatment. TB-α 
was used as loading control. Molecular weight markers are shown to the right and are expressed in kDa. The western blot 
samples appear in the following order: T24, 5637 and HT1376 Normoxic conditions (N); T24, 5637 and HT1376 Hypoxic 
conditions (H); T24, 5637 and HT1376 DFX treatment (D); B. Protein expression time course of HIF-1α and CA IX was 
measured by western blot analysis. Graphs represent average value of at least three independent experiments, flags 
correspond to SD and ***p < 0.001; **p < 0.01; *p < 0.05 
 
The metabolic shift of the cells from aerobic to anaerobic metabolism, a critical event 
underlying hypoxia, was also confirmed by increased lactate levels in hypoxic cells culture 
mediums (Figure 6). Similar behaviour was also observed upon DFX exposure, which 
suggests that HIF-1 may be the key mediator for these changes. Hypoxic tumour cells 
primarily use glucose for glycolytic energy production and release lactic acid, creating a 
lactate gradient that mirrors the oxygen gradient in the tumour. Although lactate is 
generally considered a waste product, Sonveaux et al. showed that it is a prominent 
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substrate that fuels the oxidative metabolism of oxygenated tumour cells (177). There is 
therefore a symbiosis in which glycolytic and oxidative tumour cells mutually regulate their 
access to energy metabolites. The same authors further identified monocarboxylate 
transporter 1 (MCT1) as the prominent path for lactate uptake by a human cervix 
squamous carcinoma cell line that preferentially utilized lactate for oxidative metabolism 
(177). The expression of MCT1 will also be assessed in the future in the bladder cancer 
cell models. Interestingly, HT1376 cell line shows significantly elevated basal levels of 
lactate in normoxic conditions in comparison to the other cell lines (Figure 6). A number of 
studies have shown that malignant transformation is associated with an increase in 
glycolytic flux and in anaerobic and aerobic cellular lactate excretion, which is consistent to 
the basal levels of lactate in normoxic conditions for all cell lines (178). Nevertheless, other 
mechanisms could account for the HT1376 particular case. The HT1376 elevated basal 
levels of lactate may correlate with elevated basal levels of HIF-1α, since lactate also 
stimulate the accumulation of HIF-1α, independently of hypoxia (27). In various tumour 
types investigated, high concentrations of lactate were correlated with a high incidence of 
distant metastasis already in an early stage of the disease. Moreover, recent reports show 
various biological activities of lactate that can enhance the malignant behaviour of cancer 
cells. These mechanisms include the activation of hyaluronan synthesis by tumour-
associated fibroblasts, up-regulation of vascular endothelial growth factor and HIF-1α 
itself, and direct enhancement of cellular motility that generates favourable conditions for 
metastatic spread. Thus, lactate accumulation not only mirrors but also actively enhances 
the degree of tumour malignancy, which correlate to the characteristics of grade III 
carcinoma HT1376 cells. 
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Figure 6. When exposed to hypoxic conditions all UBC cell lines actively switch to an anaerobic metabolism. All cell lines 
were cultures for 24h before exposure to any experimental conditions. After a hypoxia (0.1% O2) or DFX (500µM) exposure 
period of 24h (T24 and 5637) and 6h (HT1376), lactate levels of the cultures conditioned mediums were measured. Graph 
represents average value of three replicates, flags correspond to SD and ***p < 0.001; **p < 0.01; *p < 0.05. 
 
Altogether, bladder cancer cell lines T24 and 5637 overexpress hypoxia biomarkers 
HIF-1α and CA IX after 24h of exposure to oxygen deprivation, while for HT1376 this 
effect was already observable at 6h. Concomitantly, these cells shifted towards an 
anaerobic metabolism. The stabilization of HIF-1α with DFX resulted in similar 
behaviours suggesting that this transcription factor might regulate these events. 
 
4.2. Morphological characterization of urinary bladder cancer 
cells 
 
In normoxic conditions T24 cells show a heterogeneous appearance, i.e. cells on the 
periphery of the islands mostly present a polyhedral morphology but peripheral elongated 
cells are also present. T24 cells are pleomorphic and have more centroid nucleus than the 
other cell lines (Figure 7A). The growth of T24 cells in tissue culture was characterized by 
a disorderly pattern of growth in one or more layers and by mixed epithelioid-fibroblastoid 
morphology. These observations are consistent with the original characterization of T24 
cell line (128,129). In the course of hypoxic treatment, cells acquire a more elongated 
semblance as well as a larger intercellular space between them. These morphological 
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changes are more pronounced during DFX treatment, suggesting this might be an HIF-1α-
mediated phenomena. 
Concerning the 5637 cell line, in normoxic conditions 5637 cells present polyhedral 
morphology with the nucleus in a lateral position. Even in the inner cells of the island the 
nucleus is not the centroid of the cell. Peripheral normoxic cells also present extensive 
areas of membrane ruffling (MR). In hypoxic conditions polyhedral and elongated cells are 
present as well as membrane ruffling. This morphology can be considered as intermediate 
between normoxic and DFX conditions. When subjected to DFX treatment, cells do not 
form cohesive but dispersed islands with hook-shaped cells (HSC) in the extremities, 
which along with increased intercellular distances suggests possible cell scattering (Figure 
7B). The 5637 cell line scattering has already been reported by other authors in other 
conditions than hypoxia (130). 
Normoxic HT1376 cells present polyhedral morphology with peripheral nucleus and 
grows in islands. The existence of giant cells, large vacuoles and cytoplasmatic granules 
could be noticed in cultured cells. These cells have an extensive membrane area without 
membrane ruffling. Intercellular spaces are evident and emphasized with higher 
amplification, highlighting the cell junctions (CJ) (Figure 7C). When subjected to hypoxia 
and DFX treatment, HT1376 cells have a very similar appearance to that observed in 
normoxic conditions, suggesting these cells retain their original morphology under oxygen 
privation or that 6h treatments may not be enough to see morphological changes. The 
epithelial morphology of HT1376 cell line and the presence of citoplasmatic vacuoles were 
also reported by other authors (131). 
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Figure 7. Hypoxic conditions modify morphological traits of urinary bladder cancer cell lines. All cell lines were cultured for 
24h before exposure to experimental conditions. T24 (A) and 5637 (B) cells were then exposed to 500 µM DFX or 0.1% O2 
for 24h, while HT1376 (C) cells were exposed to the same conditions for 6h. Images were acquired using a high-resolution 
inverted microscope. CJ, cell junctions, HSC, hook-shaped cells, MR, membrane ruffling; V, vacuole. Scale bars correspond 
to 100 and 50 µm. 
 
4.3. Hypoxic modulation of EMT and Stemness 
 
As previously described, the epithelial-to-mesenchymal transition (EMT) is a process 
by which epithelial cells lose their polarity and are converted to a mesenchymal 
phenotype, which is regarded as a critical event in morphogenetic changes during 
embryonic development, wound healing and cancer metastasis (82).The hypoxic 
microenvironment emerges as an important factor in the induction of pathological EMT, 
which is a key link in cancer progression (83). According with this observations, to explore 
the events mentioned above in UBC models, the cells were further characterized in 
relation to the expression of panel of 21 genes associated with stem cell (NANOG, 
LIN28A, POU5F1, KLF9, KLF4, SOX2), epithelial (CDH1, DSP, EPCAM), epithelial-to-
mesenchymal transition (SNAI1, SNAI2, TWIST1, TWIST2, ZEB1, ZEB2, RUNX1, 
RUNX2), and mesenchymal (FN1, CDH2, VIM, SPARC) programs. The GAPDH gene was 
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selected as reference gene, since it was expressed at constant levels in all experimental 
condition and all cell lines. 
 According to the map in Figure 8A, under normoxia the T24 and 5637 cells 
presented a significant down-regulation of epithelial markers (CDH1, EPCAM and DSP) 
accompanied by an up-regulation of mesenchymal genes (CDH2, FN1, SPARC, and VIM) 
when compared to HT1376. The up-regulation of mesenchymal markers is particularly 
evident in the 5637 cell line whereas the T24 cell line showed a more marked stem cell 
character. A comparison between these two cell lines highlighted a significant (p ≤ 0.005) 
down-regulation of KLF4, CDH1, DSP and CDH2 and up-regulation of NANOG, LIN28A, 
TWIST1 and ZEB2. An integrative analysis of these differences using ClueGo and 
CluePedia showed that T24 cell line presents a significant up-regulation of pathways 
involved in stem cell development and also a profound deregulation of cell-cell adhesion, 
translated by a negative regulation of cell-cell contact and adherent junction organization, 
suggesting a higher migration potential. In resume, gene expression analysis highlights 
that both T24 and 5637 present a pronounced mesenchymal properties, with T24 
exhibiting a more pronounced stem nature. On the other hand, the HT1376 cell line 
showed a marked epithelial nature which was not found in the other two cell lines. 
Noteworthy, is that 5637 cells are close related with HT1376 from the genetic point of view 
(163); however this cell line was found more similar to T24 based on the studied gene 
expression patterns. 
Cells were then grown under hypoxia and in the presence of DFX to determine the 
influence of oxygen and HIF-1α on the gene expression pattern. According to Figure 8B, 
T24 and 5637 presented similar variations in terms of genes expression from hypoxia to 
normoxia, while HT1376 had a distinct gene expression pattern, like previously observed 
in normoxia. The most string difference between the cell lines was the up-regulation of 
epithelial-to-mesenchymal and mesenchymal markers (6/11 studied genes) in HT1376, 
which was not evident in the other cells that already presented this phenotype in normoxia. 
However, both similarities and differences could be observed between the cell lines based 
on the most significant gene variations (p ≤ 0.005) as highlighted by the Venn diagram in 
Figure 8C. In particular, at the 95% confidence level, T24 and 5637 cells significantly 
down-regulated SPARC and SNAI1 while overexpressing SNAI2 and RUNX1. On the 
other hand, T24 and HT1376 cells shared the up-regulation of FN1 and KLF4, while 5637 
and HT1376 both up-regulated ZEB2. The T24 cells distinguished from the other cell lines 
by also down-regulating KLF9 while up-regulating RUNX2. An increase in POUF1 was 
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only observed in 5637 and TWIST1 overexpression was only found in HT1376. The 
integrative analysis of these profiles using ClueGo and CluePedia (Figure 9) showed that 
T24, 5637 and HT1376 cells in hypoxia presented a positive regulation of stem cell 
development, i.e. up-regulation of any process that increases the rate, frequency or extent 
of stem cell maturation, which does not include the steps involved in committing a cell to a 
specific fate. The T24 cell line also showed up-regulated stem cell differentiation 
processes, which comprehends events that drive relatively unspecialized cells to acquire 
specialized features of a stem cell. In addition, 5637 and HT1376 cells presented an up-
regulation of biological pathways committed to mesenchymal development. Altogether, this 
data suggests that hypoxia drives bladder cancer stem cell establishment and 
mesenchymal phenotypes. 
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Figure 8. Heatmaps showing normoxic (A) and hypoxic (B) modulation of the transcript levels of a small group of 
EMT, Stem and mesenchymal markers. All cell lines were cultured for 24h before exposure to any experimental conditions. 
After hypoxia (0.1% O2) or DFX (500µM) exposure period of 24h (T24 and 5637) or 6h (HT1376), the transcript levels of a 21 
genes tailored panel were quantified by qRT-PCR C. Venn diagrams showing statistical significant data, focusing on 
overlapping patterns of gene expression in each cell line. 
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Figure 9.Unified conceptual framework integrating genetic expression data and non-redundant biological functions. 
The functional interaction network was obtained using Cytoscape Software Version 3.1.1.CluePedia and ClueGo plugins for 
FCUP 
Hypoxic Regulation of Glycosylation in Bladder Cancer 
54 
 
 
 
single cluster analysis and comparison of gene clusters in order to explore cellular processes and their dynamics. ***p < 
0.001; **p < 0.01; *p < 0.05. 
 
The cells were then compared based on variations in gene expression under hypoxia 
in relation to normoxia (conditions HN) and growth with DFX in relation to normoxia 
(conditions DN). Figure 10 allows the determination of a set of genes which are under- or 
overexpressed at any given significance level. At the 95% confidence level, some genes 
are overexpressed at both HN and DN: FN1 (HT1376), KLF4 (T24 and HT376) and SNAI2 
(T24 and 5637). More interestingly, ZEB2 (HT376) and RUNX1 (T24) would also be in this 
category, for a confidence level of 90% (Figure 10 top-right insert). Also a 95% confidence 
level, SPARC (T24 and 5637) and KLF9 (T24) were under-expressed both in DN and in 
HN (Figure 10, bottom-center insert). SNAI1 was under-expressed in HN conditions in 
both T24 and 5637 cells, but over-expressed, at a 95% confidence level, when DN 
conditions are considered (Figure 10, bottom-right insert). At a 90% confidence level, 
RUNX1 and POUF1 appeared to be over-expressed in 5637 cells in HN conditions, but 
under-expressed in DN (Figure 10, middle-right insert). Overall, Figure 10 shows that the 
weighted under- and over- expression of the tested genes in HT376 cells under hypoxia 
and under DFX treatment are moderately correlated. This allows the hypothesis that these 
cells have similar behaviour in hypoxia and in DFX, from the point of view of the activation 
of the tested genes. This behaviour is not observed for 5637 and T24 cells, again in 
accordance with previous observations of similarities between the two cell lines. 
Noteworthy, is that the SNAI2, RUNX2 and KLF4 genes that drive, together with HIF-1α, 
the stem cell character of T24 cells in hypoxia presented equal behaviour with DFX 
treatment. Likewise, SNAI2, which together with HIF-1α contributes to stem cell 
development in 5637 cells, is also modulated by DFX. Finally, KLF4 and ZEB2 that 
contribute to stem cell development in HT1376 are also suggested to be driven by HIF-1α. 
Altogether, these observations reinforce the key role played by HIF-1α in driving the stem 
cell character of bladder cancer cells. 
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Figure 10. Scatterplot analysis of gene expression data in O2 deprivation conditions (conditions HN) or under DFX treatment (conditions 
DN) in relation to normoxia. 
4.4.  Expression of STn and ST6GalNAc.I in bladder cancer cells 
 
Little is known on the expression of the tumour-associated carbohydrate antigen 
sialyl-Tn (STn) in bladder cancer. However, the cancer-specific nature of this antigen was 
already been demonstrated and the presence of STn has been strongly associated with 
the overexpression of ST6GalNAc.I in several human malignancies. The expression of 
STn in the evaluated cell lines was determined by flow cytometry and the results resumed 
in Figure 11. As shown in Figure 11A, STn is expressed by all cell lines in normoxic 
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conditions and has significant expression increase in hypoxic conditions as well as in the 
presence of DFX. The presence of STn was validated by the decrease in fluorescence in 
the FACS to levels similar to the cells auto-fluorescence after neuraminidase treatment 
(Figure 11B). 
The ST6GalNAc.I, C1GALT, and GCNT1 genes expression were quantified by the 
real-time RT-PCR method. The enzymes mRNA levels were normalized for the expression 
of GAPDH, which was taken as a suitable endogenous control for bladder cancer cells out 
of three housekeeping genes tested. Contrasting with the overexpression of STn (Figure 
11A), the mRNA levels of ST6GalNAc.I do not follow this tendency, suggesting that in 
bladder cancer models the overexpression of ST6GalNAc.I may not be the factor 
accounting for STn overexpression (Figure 11C). The reasons leading to over-expression 
of this truncated mucin-type O-glycan are multiple. Namely, in breast cancer cell lines, 
ST6GalNAc.I can override the core 1/core 2 pathway by being present throughout the 
Golgi allowing the production of large quantities of STn expressing proteins (117). 
Additionally, somatic mutations in Cosmc gene may also lead to STn overexpression, 
since loss of Cosmc results in loss of T-synthase in the Golgi apparatus and accumulation 
of Tn antigen, which can be converted to STn by the existing ST6GalNAc.I enzyme (179). 
Furthermore, increased activity of ST6GalNAc.I and/or down-regulation/decreased activity 
of several other competing glycosyltransferases could also be responsible for the results 
(94,158,165,180,181). In this particular case, a dramatic down-regulation of the C1GALT, 
and GCNT1 genes, encoding for core 1 Gal-T and core 2 GlcNAc-, responsible by further 
elongation of O-glycans (Figure 11C), could be observed for all cell lines under hypoxia 
and DFX treatment.  
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Figure 11. Bladder cancer cell lines overexpress STn in hypoxic conditions in a ST6GalNAc.I independent manner. A. Flow 
cytometry histogram overlays show stronger STn expression upon O2 deprivation and DFX treatment; Bar graph showing 
Mean fluorescence intensity (MFI) of STn signal in normoxic conditions (21 % O2) versus hypoxic conditions (0.1% O2; 500 
µM DFX). T24 and 5637 were submitted to normoxic or hypoxic condition for 24h while HT1376 cell line was submitted to the 
same condition for 6h. B. The decay of signal with neuraminidase treatments, confirms signal specificity. C. Bar graphs 
showing the ST6GalNAc.I, GCNT1 and C1GalT1 transcript levels upon hypoxia and DFX treatment. Graphs represent 
average value of three different experiment, flags correspond to SD and ***p < 0.001; **p < 0.01; *p < 0.05.  
 
Altogether, it is described for the first time that hypoxia induces the expression of 
STn in bladder cancer cells, in what appears to be a ST6GalNAc.I overexpression-
independent HIF-1α-mediated mechanism. The fact that three bladder cancer cell lines 
with different genetic and molecular backgrounds overexpress, under hypoxic conditions, 
the STn antigen strongly reinforces that its presence in bladder tumours may be, at least in 
part, governed by the microenvironment. This data also strongly suggests that STn 
overexpression in hypoxia stems from an HIF-1α-mediated down-regulation of the 
glycosyltransferases involved in the elongation of O-chains. 
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 4.5.  Cellular proliferation 
 
Hypoxic microenvironment requires cellular adaptation to stress, which includes 
decreased cell proliferation (28,74). Based on these observations, the three cell lines were 
characterized in relation to their proliferation in hypoxia and in the presence of DFX. The 
most proliferative cell line for all conditions is T24, followed by 5637, whereas the 
proliferation rate of HT1367 is the lowest (Figure 12). Furthermore, the proliferation rate of 
all tumour cells, under hypoxic conditions, is lower than the proliferation rate of the same 
tumour cells under normoxic conditions. Moreover, DFX shows a growth-inhibitory activity 
even more prominent than hypoxia itself, suggesting a key role for HIF-1 in the 
modulation of bladder cancer cell proliferation (Figure 12).  
Hypoxic conditions have been found to significantly reduce the population doubling 
time in melanoma and squamous cell carcinoma cell lines, and it was described that 
exposure of several solid tumour cell lines (A549, HCT 15, and NCI H460), T-lymphoma 
cells and ovarian cancer cells to extreme hypoxia induced cell cycle arrest, mostly in a 
HIF-1α-dependent manner (28,182,183). Furthermore, under conditions of severe hypoxia 
(0.1% O2), cultured cells may exhibit increased apoptotic rates (30,184). DFX shows a 
more prominent growth-inhibitory activity than the oxygen deprivation conditions, probably 
because the iron chelation by DFX has intrinsic anti-proliferative effects, beyond the 
consequent effects of stabilization of HIF-1α. It is well known that iron is required for the 
growth of all cells, and the capacity of DFX to inhibit DNA synthesis has been 
demonstrated in several mammalian cells. Ribonucleotide reductase, a rate-controlling 
enzyme in DNA synthesis, is one possible target for the action of the drug. Indeed, 
ribonucleotide reductase, which catalyses the enzymatic formation of 
deoxyribonucleotides, contains a free tyrosyl radical as part of its polypeptide structure that 
requires the continuous presence of oxygen and iron during regeneration. It has been 
proposed that iron is removed passively from the medium by DFX and other iron chelators, 
thus preventing regeneration of the iron radical centre. Therefore, the iron chelation by 
DFX, which results in less tyrosyl free-radical formation, could be involved in the inhibition 
of ribonucleotide reductase activity in our bladder cancer models as well (185–188). 
Moreover, DFX treatment has apoptotic effects, which might also account for this 
observations. For instance, in human lymphocytes, DFX has genotoxic effects and induces 
p53 accumulation and p53-mediated damage response, ultimately leading to apoptosis 
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(189). On the other hand, DFX-induced apoptosis is also mediated by the p38 pathway 
and a caspase-8-dependent Bid-Bax pathway (190). 
Viable but hypoxic and non-proliferating tumour cells are of particular interest, 
because it is presumed that they comprise a substantial fraction of the cells in solid 
tumours and could be the major source of chemotherapy resistant clones.  
 
 
Figure 12. Oxygen deprivation and DFX treatment have in vitro growth-inhibitory effects on bladder cancer cells. All cell lines 
were cultures for 24h before exposure to any experimental conditions. BrdU was added to the cultured cells medium and 
after a hypoxia (0.1% O2) or DFX (500µM) exposure period of 24h (T24 and 5637) and 6h (HT1376), the BrdU incorporation 
was assessed. Graph represents average value of three replicates, flags correspond to SD and ***p < 0.001; **p < 0.01; *p < 
0.05. 
 
4.6.  Invasion and proteolytic activity of urinary bladder cancer 
models 
 
As previously described, a critical event in tumour cell invasion is degradation of the 
extracellular matrix (ECM), a complex network of extracellular macromolecules such as 
collagen, proteoglycans, fibronectin, laminin and many other glycoproteins that act as a 
barrier to the invasion of cancer cells. Although several different proteases are implicated 
in ECM degradation, a special group of metalloproteinases, matrix metalloproteinases 
(MMPs), a family of zinc and calcium-dependent proteolytic enzymes, have been given 
special attention in this work, mostly because of their important roles in several cancer-
supporting cellular processes besides extracellular matrix (ECM) remodelling, such as 
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angiogenesis, apoptosis, epithelial-to-mesenchymal transition and cell proliferation (148). 
Moreover, hypoxia has been described to potentiate the migration/invasion of cancer cells, 
which is a critical step for disease progression and dissemination. Based on these 
observations, the three bladder cancer cell lines were first characterized in relation to their 
migration/invasive potential on matrigel. In normoxia T24 and 5637 cells presented higher 
invasion than HT1376; however exposure to hypoxia increased this property in all cell lines 
in comparison to normoxia (Figure 13A). Conversely, growth under oxygen deprivation in 
the presence of an anti-STn antibody significantly lowered invasion, reinforcing our 
previous observations supporting a role for STn in bladder cancer invasion (Figure 13B) 
(15,120). 
A gelatin zymography assay (Figure 13C) was then used to evaluate if these 
observations stemmed from higher MMPs activity or were a consequence of the higher cell 
motility presented by cells in hypoxia. First it was observed that MMPs activity was similar 
between the three cell lines grown under normoxia (Figure 13D), leading to conclude that 
T24 and 5637 cells crossed matrigel due to their higher migratory capacity. Such 
observations further reinforce the mesenchymal character of these cell lines previously 
suggested by morphological and gene expression analyses. Exposure to hypoxia did not 
promote a statistically significant increase in MMPs activity, again reinforcing a main role 
for motility in the context of bladder cancer hypoxic cells dissemination (Figure 13D). 
Altogether, these findings show that hypoxia enhances cell motility irrespectively of their 
morphological and genetic background in, what appears to be, a STn-expression 
dependent process. The ClueGo and CluePedia analysis, revealed in all cell lines a 
decreased rate, frequency or extent of cell adhesion molecule production by GCNT1 
down-regulation, further reinforcing that these events contribute to negatively regulate cell 
adhesion.  
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Figure 13. Hypoxia influences invasive ability but not MMP proteolytic activity in urinary bladder cancer cells. A. The invasive 
cells from 24 h hypoxic cultures and aerobic control cultures were visualized through a Leica DM2000 fluorescence 
microscope and scored in at least 12 microscopic fields (20x objective) when DAPI-counterstained nuclei passed through the 
filter pores. B. A 24h invasion assay was conducted under oxygen deprivation conditions in the presence of the anti-STn 
antibody TKH2 and the number of invasive cells visualized as previously described. C. Representative Gelatinase zymogram 
of bladder cancer cells show two bands, one corresponding to pro-MMP-2 (72 kDa) and other corresponding to pro-MMP-9 
(92 kDa). MWM are shown to the left and are expressed in kDa. D. Bar graph showing greater expression of pro-MMP-2 
over pro-MMP-9 in all cell lines with no significant changes between normoxic and hypoxic conditions. Graphs represent 
average value of three different experiment, flags correspond to SD and ***p < 0.001; **p < 0.01; *p < 0.05. 
 
4.7. STn glycoproteomic profilling  
 
The STn antigen is a post-translational modification that may be putatively 
expressed by all glycoproteins at the cell surface (105) as translated by the smear in the 
western blots presented in Figure 14. However, two high-molecular weight bands at 
approximately 250 and 200 kDa and four low molecular weight bands at 50, 37, 25 and 15 
kDa are distinguishable for all the cell lines and experimental conditions (normoxia, 
hypoxia, DFX; Figure 14A and 14B). The specificity of STn expression was confirmed by 
the disappearance of the bands upon treatment with a -neuraminidase (Figure 14C). The 
relative quantification of the main bands highlighted a common profile for 5637 and 
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HT1376 cell lines in hypoxia, characterized by an increased expression of all evaluated 
proteins in relation to normoxia (Figure 14D). Similar behaviour was observed in the T24 
cell line, but only for low MW bands. The exposure to DFX appears to modulate the 
overexpression of STn glycoproteins in T24, specifically for low molecular weight bands. 
However, for 5637 and HT1376, DFX only promoted the overexpression of high MW 
bands observed, again denoting a common behaviour at the protein level for these cell 
lines. The different profiles presented by the cells in hypoxia and DFX also suggest that 
not all glycoprotein STn expression is mediated by HIF-1; however these findings warrant 
more in depth evaluation. Altogether, these findings demonstrate that exposure to hypoxia 
translates into an alteration in the glycoprofile of bladder cancer cells, that may be 
explored to selectively target these cells. More studies are necessary to identify the STn-
expressing proteins and to determine if the alterations found by flow cytometry and 
western blot are influenced solely by alterations in glycosylation pathways and/or by the 
relative abundance of the glycoproteins carrying this antigen. This information is expected 
to translate into further understanding on the role of glycosylation on the biological and 
clinical behaviour of bladder cancer. 
Nevertheless, based on previous findings, the high MW bands are concordant with 
the presence of mucins. Namely, MUC1, a high-molecular weight transmembrane protein 
previously reported to be heavily O-glycosylated and one of the main carriers of STn 
antigen, which lead us to hypothesize that the intense staining band at 250 kDa present in 
the blot refers to MUC1 mucin (127,191,192). Other mucins were reported to have a roll in 
bladder cancer such as MUC2, MUC4 and MUC7, which may account for more than one 
high MW bands (193,194). MUC1 is expressed on the apical surface or in umbrella cells of 
the normal non-neoplastic bladder urothelium and strong expression of MUC1 was also 
observed in urothelial carcinoma. Moreover, according to the literature, it is suggested that 
high levels of expression of sialylated MUC1 are associated with an aggressive 
phenotype, which together with its hypoxia-mediated overexpression may contribute to a 
more malignant phenotype of 5637 and HT1376 cell lines (195). Since, the decrease in 
high MW proteins is accompanied by an increase in low MW proteins in T24 cell line, one 
can hypothesise that the low MW species observed could result from the proteolysis of 
high MW proteins/ mucins. This hypothesis lines with the identification of a pathway of 
EGF (epidermal growth factor)-dependent metastasis that requires a Src (tyrosine-protein 
kinase)-mediated MUC1 proteolysis (196,197). The authors report that EGF stimulation 
induces MUC1 cleavage, leading the MUC1 cytoplasmic domain transmembrane subunit 
FCUP 
Hypoxic Regulation of Glycosylation in Bladder Cancer 
63 
 
 
 
(MUC1.CD) (15kDa) to translocate to the nucleus, where it promotes the expression of a 
metastatic gene signature associated with epithelial-to-mesenchymal transition. Those 
results showed that EGFR and Src activity, and consequently proteolytic cleavage of 
MUC1, contribute to tumour metastasis. Nevertheless, these observations need to be 
validated in a large number of patients and efforts should be conducted to identify these 
glycoproteins and disclose their contribution to malignancy. Other works correlate STn 
expression with invasion and metastatic potential in bladder cancer which associated with 
this observations could suggest an important role of sialylated MUC1 in the metastatic 
potential of our models as well (15).The other low MW bands might be a result of similar 
cleavage processes of high MW mucins (198,199). 
As previously described, 5637 and HT1376 cell lines belong to the same molecular 
pathway of bladder cancer carcinogenesis which may account for the similarities in STn 
pattern even in response to hypoxia. On the other hand, T24 cell line follows another 
molecular pathway of carcinogenesis and has a somewhat different STn pattern. In 
addition, the differential STn pattern between cell lines and experimental conditions vouch 
the importance of glycosylation as biomarker reflecting not only genetic differences but 
environmental pressures as well.  
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Figure 14. STn expression pattern in urinary bladder cancer cells, as analysed by western blotting. A. Using a 10µg protein 
input, two intense bands at approximately 250 and 200 kDa are present in all cell lines and experimental conditions, 
suggesting an association between STn expression, mucins and malignancy. The molecular weights/ kDa are shown on the 
left. All cell lines and all conditions presented low-molecular weight bands between 50 kDa and 15kDa. The optical density 
(OD) of the bands was estimated and normalized in relation to GAPDH, previously observed to be a stable housekeeping 
gene in this bladder cancer cell lines. The bands were then classified in relation to their intensity for comparison purposes. B. 
To better analyse the STn profile regarding the low molecular weight bands, a new WB using a 20µg protein input was 
carried out. C. To determine the specificity of the low-molecular weight bands a Neuraminidase enzyme treatment was 
applied. Because Neuraminidase cleaves the glycosidic linkages of neuraminic/sialic acids, the STn structure is disrupted 
preventing TKH2 linkage. The western blot samples appear in the following order: T24, 5637 and HT1376 Normoxic 
conditions (N); T24, 5637 and HT1376 Hypoxic conditions (H); T24, 5637 and HT1376 DFX treatment (D). D. Bar graph 
showing differences in optical densities of the bands between experimental conditions. 
 
4.8. HIF-1α, CA IX and STn expression in bladder tumours 
 
The expression of hypoxia markers HIF-1α and CA IX and cancer-associated glycan 
STn was evaluated by immunohistochemistry in a series including 30 NMIBC tumours and 
43 MIBC tumours, randomly selected, representing all stages of the disease (15 pTa, 15 
pT1, 13 pT2, 15 pT3, 15 pT4), to disclose associations between altered glycosylation and 
hypoxia.  
All studied tumours were positive for HIF-1α and approximately 70% presented an 
extensive expression (> 20% of the tumour area), irrespectively of their stage. HIF-1α was 
predominantly detected in the tumour cells cytoplasm but also in the nucleus, where it acts 
has a transcription factor. However, 43% of NMIBC (13/30) and 85% of MIBC (37/43), 
presented both cytoplasmic and nuclear HIF-1α expressions, demonstrating an 
association between the presence of the protein in the nucleus and advanced stage 
bladder cancer (p < 0.005). The nuclear HIF-1α positive tumours were further re-classified 
according to the degree of STn expression (Table IV). Table III shows that high nuclear 
expression was present in only 43% of the NMIBC (pTa and pT1) and in 72.1% of the 
MIBC (pT2, pT3 and pT4), reinforcing previous association of nuclear HIF-1α expression 
with muscle invasion (p < 0.05). Altogether, these findings strongly suggest an association 
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between high hypoxia levels and muscle invasive bladder cancer. The CA IX, a cell-
surface protein up-regulated by HIF-1α under hypoxic conditions, was highly expressed in 
all tumours (> 30% of the tissue). However, as expected, CA IX expression was 
significantly overexpressed (> 50%) in tumours presenting high levels of nuclear HIF-1α. 
Regarding the evaluation of STn antigen, table IV shows the frequency of STn 
presence along the different stages of the disease. Higher STn expression was observed 
for MIBC (60%) when compared to NMIBC (30%), demonstrating an association of the 
antigen with muscle invasion (p= 0.03), in accordance with previous observations. The 
expression of HIF-1α and STn was further evaluated and it was found that all the tumour 
areas in which STn is expressed presented HIF-1α nuclear expression. Moreover, high 
expression of STn antigen co-localized with high nuclear HIF-1α expression in 75% of the 
cases, irrespectively of their stage. 
 
Table III – Correlation between tumour stage and nuclear HIF-1α expression 
 
 
 
Table IV – Correlation between STn and HIF-1α expression 
 
 
 
 
 
 
Tumour stage High HIF-1α nuclear expression
Ta 4/15 (26.7%)
T1 9/15 (60%)
T2 9/13 (69%)
T3 10/15 (66.7%)
T4 12/15 (80%)
Total 44/73 (60.3%)
NMIBC 
13/30 (43%)
MIBC 31/43 
(72.1%)
P<0.05
Tumour stage STn + Tumours with STn/ HIF-1α  nuclear positive areas
Ta 3/15 (20%) 3/4 (75%)
T1 6/15 (40%) 4/6 (67%)
T2 6/12 (50%) 3/4 (75%)
T3 10/15 (67%) 7/9 (78%)
T4 9/15 (60%) 2/3 (67%)
Total 33/72 (47%) P=0.03 19/26 (73%)
NMIBC 9/30 
(30%)
MIBC 25/42 
(60%)
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V. Concluding remarks and Future perspectives 
 
The STn antigen is considered a pancarcinoma antigen, based on the fact that it is 
expressed by the majority of advanced stage solid tumours, while absent from the 
corresponding healthy tissues. It is also far from being an innocent bystander in the 
disease outcome, since it was found to be a promoter of invasion and disease 
dissemination in many models, including stomach, pancreas and breast (120,165) 
carcinomas. In agreement with these observations our group has recently demonstrated 
that STn is expressed by over 70% of advanced stage bladder cancers, in poorly 
proliferative tumour areas and invasion fronts. Moreover, we found that STn expression 
enhanced the motility and invasive potential of cancer cells in vitro and are now detecting 
the antigen in lymph node and distant bladder cancer metastasis (unpublished data). 
Subsequent studies concluded that STn-expressing cancer cells impair DC maturation and 
promote a tolerogenic function, limiting their capacity to trigger protective anti-tumour T cell 
responses (156). Altogether these findings suggest that STn positive cells are endowed 
with the capability to invade and disseminate throughout the organ and to distant locations, 
while avoiding immune surveillance. Based on these observations we envisage that STn 
antigens and, in particular, STn expressing glycoproteins are potential targets to 
circumventing tumour-induced tolerogenic mechanisms and to avoid disease progression. 
Nevertheless, and despite the key role of STn expression in cancer, the events 
responsible by this premature stop in elongation of O-glycans by sialylation of the Tn 
antigen are largely unknown. To this date two main mechanisms have been described: i) 
the overexpression of ST6GalNAc.I, which is commonly observed; ii) loss-of-function 
mutations in C1GALT1 chaperone Cosmc, described by few reports. This work now 
demonstrates, for the first time, that hypoxia, a salient feature of solid tumours, is the main 
promoter of STn overexpression in bladder cancer.  
We started by submitting three bladder cancer cell lines showing different genetic 
backgrounds to hypoxia and observed an overexpression of HIF-1α, CA IX and increased 
lactate levels in the culture media, denoting a shift to anaerobic metabolism. All cells 
responded similarly, by showing altered cellular morphology, characterized by increased 
intercellular spaces, impaired proliferation and enhanced cell migration. This was also true 
for cells growing the presence of DFX, highlighting these are HIF-1α-mediated events. 
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However, a gene expression analysis of genes associated with stem cell, epithelial cell, 
epithelial-to-mesenchymal and mesenchymal cell programs highlighted significant 
similarities between T24 and 5637 in normoxia as well as hypoxia; interestingly 5637 cells 
were regarded as genetically related to HT1376. Based on these observations we 
concluded that T24 and 5637 cells present a more mesenchymal nature, with T24 being 
markedly more immature, whereas HT1376 presents a more epithelial nature. Moreover, 
hypoxia up-regulated SNAI2, KLF4 and FN1 genes in a HIF-1α- mediated process, thus 
activating EMT and stem gene programs in all cell lines. Concomitantly, and despite 
morphological, genetic and molecular differences, all cells overexpressed the STn antigen 
in hypoxia, which translated in higher cell migration/invasion mediated by this antigen. 
More interestingly, STn overexpression was not linked to an overexpression of 
ST6GalNAc.I but to a striking down-regulation of the enzymes that participate in the 
downstream elongation of O-glycans. This highlights a new mechanism by which bladder 
cancer cells, probably of stem cell nature, acquire migration capacity in response to the 
hypoxic challenge. The effect was reverted by reoxygenation of the cells, denoting an on-
off switch which endows bladder cancer cells with the capability to escape hypoxic niches 
and ultimately colonize distant locations. These observations may acquaint for the focal 
expression of STn in bladder tumours and in the metastasis (unpublished data). Cells 
grown in the presence of DFX also overexpressed the STn antigen, suggesting that HIF-
1α may play an active role in the modulation of the glycophenotype by direct or indirect 
modulation of O-glycosyltransferases transcription. Studies on a retrospective series of 
bladder tumours comprehending all stages of the disease has confirmed the associations 
between hypoxia, translated by the nuclear overexpression of HIF-1α, and elevated STn. 
The high STn and nuclear HIF-1α phenotypes was predominantly observed in MIBC, also 
in accordance with in vitro studies. In previous studies we also reported that STn positive 
cells are mainly present in non-proliferative niches, which present high resistance to 
cisplatin-based regimens used in bladder cancer treatment. Here we observed that STn 
overexpression under hypoxia was accompanied by a decrease in cell proliferation. 
Imagiological studies by imagestream flow cytometry are ongoing to determine the cell 
cycle phase of STn positive cells envisaging understanding its susceptibility to 
chemotherapy. Furthermore, we aim to also determine if the presence of this antigen 
contributes positively to the mitigation of cell proliferation. It would also be important to 
confirm the capability of STn positive cells to form metastasis and recapitulate tumour 
heterogeneity in distant locations. Given the pancarcinoma nature of the STn antigen, 
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studies should be conducted to understand if hypoxia promotes similar alterations in cell 
lines from other organs. Finally, a preliminary glycoproteomic study has showed that 
bladder cancer cells under hypoxia overexpress low molecular weight STn-positive 
proteins (< 50 kDa). The future identification of the proteins responsible by this distinct 
pattern by Mass Spectrometry-based proteomics are expected to provide highly specific 
theranostic biomarkers to improve bladder cancer management. Furthermore, this will 
bring more insights about the biological significance of STn expression in bladder cancer 
but also other advanced stage tumours that also overexpress this antigen. 
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